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RNA editing is generally defined as the alteration of an RNA sequence 
from that encoded by the genome through nucleotide insertion, deletion or 
modification.  The Apolipoprotein B mRNA Editing Catalytic polypeptide 1 
(APOBEC1) cytidine deaminase is an mRNA editing enzyme that modifies a 
specific cytidine in the apolipoprotein B (apoB) transcripts of small intestine 
enterocytes.  APOBEC1-mediated cytidine to uridine editing generates an in-
frame stop codon and results in translation of a truncated apoB isoform with 
distinct functions in lipid transport.  Other physiological mRNA targets of 
APOBEC1 editing have remained largely unknown. 
 This thesis presents the development of an RNA-Seq method for the 
identification of mRNA editing events on a transcriptome-wide scale and its 
application to the discovery of APOBEC1 editing targets in small intestinal 
enterocytes.  The technique utilizes ultra-high throughput sequencing and 
subsequent bioinformatic analysis to compare wild-type and congenic apobec1-/- 
transcriptomes for specific single nucleotide variants indicative of editing. 
Following technical validation, the screening approach was used to 
identify more than 30 previously undescribed APOBEC1 editing sites in 
enterocyte mRNA. All of the newly identified sites are located in AU-rich 
segments of transcript 3’ untranslated regions (3’ UTRs).  Furthermore, these 
sites share several characteristic sequence features, including flanking nucleotide 
preferences and a downstream (3’) APOBEC1 mooring motif.  Sequence pattern 
recognition analysis based on these features successfully predicted additional 
APOBEC1 targets.   
The studies detailed here demonstrate the feasibility and utility of a novel 
transcriptomics approach to RNA editing studies.  The corresponding results 
indicate that APOBEC1 site-specifically edits many mRNA transcripts other than 
apoB in small intestinal enterocytes, suggesting additional roles for APOBEC1 
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CHAPTER 1: INTRODUCTION 
An organism’s genome contains the complete set of information required 
for its development, function, survival and reproduction.  This exceedingly 
complex biological compilation is encoded entirely by the four nucleotides of 
DNA: adenine, cytosine, guanine and thymine.  Changes in nucleotide sequence 
can directly impact the information content encoded therein, with corresponding 
functional consequences.  As the properties of DNA, RNA and proteins are 
determined by their sequences, molecular biology can be thought of as an 
information science.  All life is dependent on the maintenance, interpretation and 
replication of vast amounts information represented by linear biopolymers 
composed of simple components. 
 The human genome contains approximately 25,000 genes (Consortium, 
2004).  This is only about twice that of the fruit fly (Adams et al., 2000; Misra et 
al., 2002) and four times that of the baker’s yeast (Goffeau et al., 1996; Mewes et 
al., 1997).  Considering the complexity of the human organism, this number 
seems surprisingly small.  As fixed units, it is unlikely that 25,000 genes could 
allow for sufficient informational content to represent the complexity of 
mammalian life.  Therefore, numerous mechanisms exist to impart additional 
diversity and complexity to the genome, transcriptome and proteome. 
Programmed changes in genomic DNA are rare, likely due to its heritability and 
the potentially deleterious effects of off-target errors.  However, immune cells 
rely on somatic recombination and mutation to diversify their antigen receptors.  
In contrast, proteins are subject to extensive post-translational modifications that 
can have long- and/or short-term impact on their functionality.  Changes at the 
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RNA level, however, represent perhaps the most significant source of complexity 
in the content and regulation of the expressed proteome. 
 As transitory reproductions of information permanently “hard coded” in 
the genome, RNA transcripts can undergo many types of diversity-promoting 
alterations without compromising the genetic integrity of the cell.  Alternative 
mRNA splicing generates a dramatic increase in transcriptome complexity.  Most 
mammalian genes contain multiple exons and more than 75% are estimated to 
have at least 2 alternatively spliced transcript isoforms (Kampa et al., 2004).  
Through the combinatorial generation of different mature transcript forms, 
alternative splicing increases the number of unique “functional genes” (i.e. 
distinct proteins) by a considerable factor.  Additionally, other post-
transcriptional processing events can alter start codon usage, affecting the length 
or reading frame of translated proteins.  Differential poly-adenylation patterns 
can influence transcript stability and regulation.  
Though all of these processes alter the content of RNA transcripts, they do 
so by including or excluding sequence blocks encoded by genomic DNA without 
modifying the individual nucleotides.  Additional diversity is imparted by RNA 
editing processes, in which the primary sequence of an RNA transcript is 
modified by chemical changes to its nucleotide content.  As such, RNA editing is 
a flexible mechanism for introducing very precise alterations to the 
transcriptome at single nucleotide resolution.  Such seemingly minor changes to 
nucleotide sequence can have functional consequences ranging from the subtle to 
the dramatic in a variety of biological contexts. 
2
 
1.1.  RNA Editing – An Overview 
 RNA editing is generally defined as the co- or post-transcriptional 
alteration of an RNA sequence from that encoded by the genome through 
nucleotide insertion, deletion or modification (Wedekind et al., 2003).  Though 
not all editing mechanisms are evolutionarily related, RNA editing has been 
observed in all domains of life: Archaea, Bacteria and Eukarya.  The substrates 
and functional outcomes of editing are extremely varied; editing can impact 
RNA structure, base pairing, and RNA-protein interactions.  In mRNA, editing 
can create, delete or alter codons, introduce novel splice sites, and modulate 
transcript stability and regulation (Bass, 2002). 
1.1.1.  Uridine Insertion/Deletion Editing 
 The two primary mechanisms of RNA editing are uridine 
insertion/deletion editing and base modification editing.  Uridine 
insertion/deletion has been observed in the mitochondrial gene transcripts of the 
kinetoplastids, including Trypanosoma brucei and Leishmania tarantolae.  
Mitochondrial gene expression by these flagellated protozoa requires a series of 
complex RNA processing events, which for many genes involves the insertion 
and/or deletion of uridine residues within the transcripts’ primary sequence.  
Initial examinations of different kinetoplastid mitochondrial gene sequences 
revealed aberrant cryptogenes: sequences with similarity to essential 
mitochondrial genes but distorted with frameshift mutations (Benne et al., 1986), 
missing start codons and/or tracts of absent coding sequence (Simpson et al., 
1987).  Following the recognition that T. brucei cytochrome oxidase subunit II 
(coxII) mRNA contains additional uridines that effectively “repair” a genome-
3
 
encoded frameshift (Benne et al., 1986), RNA editing was recognized as an 
important mechanism for functional gene expression. 
 Uridine insertion/deletion editing in kinetoplastids is a complex process 
mediated by numerous protein and RNA components.  The information for 
editing at particular sites is specified by guide RNAs (Blum et al., 1990; Sturm 
and Simpson, 1990b), most of which are encoded by kinetoplastid minicircle 
DNA (Sturm and Simpson, 1990a).  Based on sequence complementarity in their 
5’ anchor region, guide RNAs form heterohybrids with target mRNAs and 
provide a template for the insertion (Blum et al., 1990; Sturm and Simpson, 
1990b) or deletion (Seiwert and Stuart, 1994) of uridines by Watson-Crick and 
G:U base-pairing rules.  Nucleotide insertion or deletion is performed by 
different multimeric protein complexes (Schnaufer et al., 2003), which contain 
RNA ligase, U-specific exonuclease, site-specific endonuclease, uridylyl 
transferase and numerous RNA binding proteins (Aphasizhev et al., 2003; 
Panigrahi et al., 2003a; Panigrahi et al., 2003b; Simpson et al., 2004; Stuart et al., 
2004).  Editing has been observed in more than half of kinetoplastid 
mitochondrial mRNAs (Feagin et al., 1988; Shaw et al., 1989; Shaw et al., 1988) 
and is essential for kinetoplastid survival (Schnaufer et al., 2001). 
 Uridine insertion/deletion RNA editing is unique to kinetoplastids.  
Given the complexity and considerable metabolic cost of this process, it remains 
unclear as to why this editing mechanism was selected for and maintained in 
these organisms.  One theory speculates that editing evolved to repair mutations 
accumulated in the mitochondrial genomes of ancestral anaerobic kinetoplastids 
(Cavalier-Smith, 1997).  Another model suggests that editing at the RNA level 
provides flexibility for sequence and functional adaptation, allowing for 
4
 
increased genome mutation rates, genetic variation and selection (Landweber 
and Gilbert, 1993).  RNA editing might also function as a regulatory mechanism 
to optimize energy metabolism in the different life stages of the kinetoplastid 
(Stuart et al., 1997).  In African trypanosomes, different mitochondrial mRNAs 
are edited during the life cycle stage that employs oxidative phosphorylation as 
compared to stages in which glycolysis is utilized for energy production (Feagin 
et al., 1987).  Though its evolutionary history remains unclear, kinetoplastid 
mRNA editing presents a remarkable example of atypical management of 
biological information.  
1.1.2.  Base Modification Editing 
 While uridine insertion/deletion editing has been observed only in 
kinetoplastids, base modification RNA editing occurs in all forms of life.  Though 
many site-specific nucleotide modifications (e.g. methylation, acetylation, 
glycosylaton) occur in RNA (Rozenski et al., 1999), base modification RNA 
editing traditionally refers to the enzymatic deamination of an encoded base to 
create a substitute nucleotide.  Polynucleotide cytidine deaminases convert 
cytidine to uridine (C-to-U, Figure 1.1), while polynucleotide adenosine 
deaminases convert adenosine to inosine (A-to-I, Figure 1.2).  In both cases, the 
RNA phosphodiester backbone remains intact. 
 In the evolution of prokaryotes and eukaryotes, tRNA represents a 
common progenitor substrate for RNA editing.  In bacteria and chloroplasts, 
tRNAArg2 contains an inosine nucleotide at position 34, the first (5’) base of the 
anticodon sequence (Limbach et al., 1994; Sprinzl et al., 1996).  Similarly, seven or 

















Figure 1.1. C-to-U editing by polynucleotide cytidine deaminases. The 















Figure 1.2. A-to-I editing by polynucleotide adenosine deaminases. The 





with three different RNA nucleotides: U, C, and A.  This non-standard coupling 
property, along with G:U base pairing, forms the mechanistic basis for Crick’s 
wobble hypothesis (Crick, 1966), in which the degeneracy of the genetic code is 
partially a result of single tRNA anticodons recognizing multiple, synonymous 
mRNA codons.  The genes encoding these tRNAs all contain an adenosine at 
position 34; inosine is introduced by post-transcriptional RNA editing. 
 tRNA anticodon editing is carried out by adenosine deaminases acting on 
tRNA (ADATs).  In bacteria, homodimeric TadA/ecADAT2 catalyzes the A-to-I 
editing at position 34 of tRNAArg2 (Wolf et al., 2002).  The site-specificity of this 
reaction is determined primarily by the sequence of the anticodon loop substrate.  
tadA is essential for cell viability, which underscores the functional importance of 
wobble recognition in even a single tRNA.  The TadA homolog in eukaryotes is a 
heterodimer (Tad2p/ADAT2 and Tad3p/ADAT3), which edits multiple tRNAs 
and exhibits broader specificity than its evolutionary predecessor (Gerber and 
Keller, 1999).  ADAT1, a related eukaryotic enzyme, edits tRNAAla  at an 
adenosine nucleotide at position 37, immediately adjacent to the anticodon 
sequence (Gerber et al., 1998; Maas et al., 1999).  The functional consequence of 
this modification is not clear, though it may be important for suppressing 
translational frameshift errors.  Though adenosine to inosine changes constitute 
only a small fraction of the numerous base modifications present in tRNAs, they 
serve an essential and fundamental role, as evidenced in part by the broad 
evolutionary conservation of the ADAT editing machinery. 
 As perhaps the first evolutionary instance of polynucleotide RNA editing 
enzymes, the ADAT family provides mechanistic insight into the subsequent 
emergence of editors that act on mRNA and DNA substrates.  Despite the 
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adenosine-to-inosine activity of the ADATs, their catalytic domains bear 
considerable similarity to those of the cytidine deaminases (Gerber and Keller, 
1999).  This characteristic zinc-dependent deaminase motif, [H/C]xEx25-30PCxxC 
(where X is any amino acid), is also present in the prokaryotic mononucleotide 
cytidine deaminases (Betts et al., 1994; Ireton et al., 2002; Johansson et al., 2002; 
Xiang et al., 1997).  An evolutionary shift in ADAT substrate specificity (i.e. from 
C to A) was probably the result of changes to the nucleotide binding properties 
of the enzyme active site.  The sequence and structural similarities of adenosine 
and cytidine polynucleotide deaminases underscore the biochemical similarities 
of these two forms of base modification editing.  Indeed, the trypanosomatid 
ADAT2/3 complex has the flexibility to perform both A to I editing in tRNA as 
well as C to U editing in DNA (Rubio et al., 2007).  This permissive specificity 
provides functional evidence of an evolutionary relationship in which the 
cytidine deaminase motif-containing ADAT family diverged into the ADAR 
adenosine deaminases and AID/APOBEC polynucleotide cytidine deaminases 
(Conticello, 2008; Conticello et al., 2007). 
9
 
1.2.  Adenosine Deaminases Acting on RNA (ADARs) 
 The ADAR family of RNA editing enzymes emerged early in metazoan 
evolution, a result of ADATs gaining double-stranded RNA binding function (Jin 
et al., 2009).  ADARs have been identified in most multicellular organisms 
examined, including worm (Tonkin et al., 2002), fly (Palladino et al., 2000b), fish 
(Slavov et al., 2000a; Slavov et al., 2000b), frog (Bass and Weintraub, 1987, 1988; 
Rebagliati and Melton, 1987), bird (Herbert et al., 1995), rodent (Melcher et al., 
1996b; O'Connell et al., 1995) and human (Kim et al., 1994).  The ADAR proteins 
contain a variable number of double-stranded RNA binding motifs (dsRBMs) 
followed by a C-terminal catalytic domain with similarities to the cytidine 
deaminase motif described above. ADARs bind to RNA duplex structures and 
catalyze the conversion of adenosine to inosine.  A-to-I modification is the most 
common mRNA editing event in higher eukaryotes, and is important if not 
essential for animal life.  Deletion of ADAR genes in mice results in embryonic 
lethality (ADAR1) (Hartner et al., 2004; Wang et al., 2004b) or severe 
neuropathology and early post-natal mortality (ADAR2) (Higuchi et al., 2000).  
Drosophila melanogaster mutants lacking ADAR activity display severe behavioral 
defects, seizures and paralysis (Palladino et al., 2000a).  Such dramatic 
phenotypes underscore the significance of proper information management in 
the transcriptome and the impact of RNA editing on its regulation. 
 Unlike their ADAT evolutionary precursors, ADARs act on a diverse 
array of cellular transcripts.  Three ADAR proteins have been identified in 
mammals; ADAR1 and ADAR2 both demonstrate broad specificity for editing 
targets (Riedmann et al., 2008), while ADAR3 does not exhibit detectable 
catalytic activity (Chen et al., 2000; Melcher et al., 1996a).  ADAR editing targets 
10
 
include mRNA coding sequences, mRNA untranslated regions, splice sites, 
introns, transcribed Alu/SINE elements, pre-miRNA transcripts and viral RNA.  
A-to-I modification in these different RNA substrates can result in various 
functional consequences. 
1.2.1. mRNA Coding Sequence Targets of ADAR Editing 
 ADAR targets in mRNA coding sequences provide the most direct 
examples of editing impact on biological outcomes.  Inosine is read as guanosine 
by the translational machinery (Basilio et al., 1962), so A-to-I editing effectively 
induces A to G sequence alterations in protein coding information.  Editing 
events that result in non-synonymous codon changes contribute to considerable 
proteome diversity in several tissues, particularly brain.  For example, ADAR2 
edits the mRNA encoding the glutamate-gated ion channel AMPA receptor 
subunit GluR-B at a specific adenosine termed the Q/R site (Sommer et al., 1991). 
Upon translation, inosine at this position results in an ion channel protein 
product with notable functional differences relative to the non-edited isoform, 
including decreased calcium permeability and altered channel dynamics (Lomeli 
et al., 1994).  The severe neuropathologic phenotype of adar2-/- mice can be 
rescued by introducing a single point mutation at the Q/R site within the GluR-B 
gene, demonstrating the physiological significance of this editing event (Higuchi 
et al., 2000).  Though an arginine residue at the GluR-B Q/R position is critical in 
the adult brain, editing provides a functional flexibility that may be important in 
brain development and plasticity.  Such flexibility is apparent in many other 
ADAR-targeted gluR subunit mRNAs, for which edited and non-edited isoforms 
11
 
coexist and can be developmentally regulated (Bernard and Khrestchatisky, 1994; 
Lomeli et al., 1994). 
 The 5-HT2CR serotonin receptor mRNA is another neurotransmitter 
transcript that undergoes coding sequence changes as a consequence of ADAR 
editing.  5 different A-to-I editing sites are present in the 5-HT2CR  mRNA, each 
of which results in a single amino acid substitution (Burns et al., 1997; Niswender 
et al., 1998).  The protein sequence changes alter the affinity of the serotonin 
receptor for G protein coupling, which in turn affects ligand binding affinities 
and downstream signaling.  Combinatorial editing can lead to many different 5-
HT2CR protein isoforms (Burns et al., 1997; Niswender et al., 1999), which exist at 
different levels in different parts of the brain (Burns et al., 1997).  The variety 
obtained from a single primary transcript demonstrates the potential impact of 
RNA editing on proteome diversification, a particularly important feature in an 
exceedingly complex tissue such as the brain. 
1.2.2. Untranslated RNA Sequence Targets of ADAR Editing 
 In addition to neurotransmitter receptors, ADAR coding sequence editing 
has been observed in several other cellular mRNAs for proteins of various 
function, including the actin-binding protein filamin A, bladder cancer 
associated protein (blcap) and insulin-like growth factor binding protein 7 
(Levanon et al., 2005; Riedmann et al., 2008).  However, recent bioinformatic 
(Athanasiadis et al., 2004; Blow et al., 2004; Kim et al., 2004; Levanon et al., 2004) 
and ultra-high throughput sequencing analyses (Li et al., 2009b) have shown that 
most A-to-I mRNA editing occurs in untranslated transcript regions and non-
coding RNAs.  In particular, Alu elements in transcript 3’ UTRs and introns are 
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the most frequent targets of A-to-I editing in a variety of tissues.  Alu sequences 
are short repetitive retrotransposable elements interspersed throughout primate 
genomes (Cordaux and Batzer, 2009).  Alu sequences do not code for protein, but 
are often transcribed within the untranslated regions and introns of mRNAs.  
More than 10,000 A-to-I editing sites have been identified in Alu sequences 
(Levanon et al., 2004), though many of these occur within introns that may be 
spliced out and therefore absent from mature transcripts.     
The functional consequences of A-to-I changes in Alu and other 
untranslated sequences are somewhat unclear, but recent work suggests that 
editing may play a role in gene regulation.  Editing in transcript 3’ UTRs 
correlates with a reduction in protein expression (Chen et al., 2008).  The specific 
mechanism for decreasing expression remains undefined, but may result from 
the nuclear retention of those transcripts with inosine-containing 3’ UTRs (Chen 
and Carmichael, 2008).  Other possibilities include sequence-dependent changes 
in RNA stability, structure and/or recognition by regulatory RNA binding 
proteins.  Examples of A-to-I editing that generate miRNA seed target sequences 
in transcript 3’ UTRs have also been described (Borchert et al., 2009).  Regardless 
of mechanism, the observation that post-transcriptional alterations in 
untranslated regions can affect mRNA processing and/or translation serves as a 
prime example of the functional significance of non-coding sequences.  Though 
such sequences do not directly code for polypeptide assembly, they can contain 
information relevant to transcript and protein regulation. 
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1.2.3. Viral RNA targets of ADAR Editing 
 A-to-I RNA editing is not limited to cellular transcripts; ADARs act on 
viral RNA as well.  ADAR1 expression is inducible by Type I interferon, 
suggesting a likely function in the host antiviral response.  However, in different 
contexts, it seems that ADAR targeting of viral RNA can benefit the host cell 
and/or the infecting virus. A to I editing has been observed in diverse viral 
RNAs, including influenza virus (Tenoever et al., 2007), parainfluenza virus 
(Murphy et al., 1991), lymphocytic choriomeningitis virus (LCMV) (Zahn et al., 
2007), vesicular stomatitis virus (O'Hara et al., 1984), measles virus (Baczko et al., 
1993; Cattaneo et al., 1988), polyomavirus (Kumar and Carmichael, 1997), and 
hepatitis D virus (HDV) (Luo et al., 1990). Despite an early recognition of A to I 
biased hyperediting in viral transcripts during persistent and lytic infections 
(Cattaneo, 1994), the function and consequences of many of these editing events 
is still under investigation.  A clear example of direct ADAR antiviral editing has 
been observed in LCMV RNA transcripts, in which large numbers of A-to-I 
mutations disrupt glycoprotein coding sequences and impair viral infectivity 
(Zahn et al., 2007).  A-to-I editing may also impair RNA viral infection though an 
inosine-specific RNAse (Scadden and Smith, 1997, 2001).  Additional evidence 
suggests that inosine-containing viral RNA might recruit specific RNA-binding 
proteins that can suppress replication and/or translation (Zhang and 
Carmichael, 2001). 
ADAR editing of viral RNA is not always inhibitory to the virus.  In 
apparent contradiction to the anti-viral functions described above, ADAR 
proteins can also promote viral replication and production.  In HIV infection, 
ADAR1 enhances viral protein expression, replication, and infectivity through 
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both editing-dependent and editing-independent mechanisms (Doria et al., 
2009).  Specific targets of A-to-I editing in HIV RNA have been identified in the 
5’ UTR shared by all HIV transcripts (Doria et al., 2009), as well as in an env gene 
protein coding sequence (Phuphuakrat et al., 2008).  In HDV infection, ADAR1 
editing is a necessary process in the virus life cycle.  Though it co-opts hepatitis B 
virus (HBV) surface antigen for capsid formation, HDV also encodes its own 
surface antigen (HDVAg).  HDVAg occurs in short (HDVAg-S) and long 
(HDVAg-L) isoforms, essential for viral replication (Kuo et al., 1989) and 
packaging (Chang et al., 1991; Ryu et al., 1992), respectively.  These two isoforms 
are regulated by ADAR1 editing, which targets a specific “amber/W site” in the 
HDV antigenome to convert a UAG stop codon (translating to HDVAg-S) to a 
UIG tryptophan codon (translating to HDVAg-L) (Casey and Gerin, 1995; Luo et 
al., 1990; Polson et al., 1996).  This editing event serves as a regulatory switch that 
shifts the HDV infection cycle from viral genome replication to virion assembly 
and packaging. 
1.2.4.  Sequence and Structural Characteristics of ADAR Editing Targets 
With diverse targets in coding exons, untranslated regions, introns and 
viral RNAs, ADAR enzymes appear to have a broad specificity for many 
different sequence types.  However, all ADAR targets share several characteristic 
sequence and structural features that determine enzyme binding and editing 
specificity.  ADAR editing sites always occur in double-stranded RNA (dsRNA) 
structures (Hundley and Bass, 2010).  In fact, prior to recognition of their editing 
activity, the ADARs were first identified as dsRNA-unwinding enzymes (Bass 
and Weintraub, 1987; Rebagliati and Melton, 1987).  RNA duplex binding is 
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dictated by the dsRBMs present in all ADAR enzymes (Stephens et al., 2004; Xu 
et al., 2006).  However, not all dsRNA structures support ADAR editing.  To 
qualify as an ADAR substrate, an RNA duplex must be of sufficient length to 
allow binding of all dsRBMs (Hundley and Bass, 2010).  In the case of ADAR2, 
the duplex must also be long enough to support the binding of a second ADAR2 
monomer, thereby establishing the dimeric complex required for editing 
(Chilibeck et al., 2006; Cho et al., 2003; Gallo et al., 2003; Jaikaran et al., 2002).  
Within a perfectly paired RNA duplex of sufficient length, ADAR editing is non-
specific (Nishikura et al., 1991; Polson and Bass, 1994); multiple adenosines will 
be deaminated until the double-stranded structure is unwound due to I:U 
mismatches (Bass and Weintraub, 1988; Wagner et al., 1989).  However, site-
specific editing is defined by structural features such as bulges, mismatched base 
pairs, and internal loops (Dawson et al., 2004; Lehmann and Bass, 1999; Ohman 
et al., 2000), as well as the nucleotides immediately adjacent to the edited 
adenosine.  With respect to an editing site, both ADAR1 and ADAR2 exhibit a 
similar preference for the 5’ neighboring base (A = U > C > G) (Lehmann and 
Bass, 2000; Polson and Bass, 1994).  ADAR2 also has a preference for the 3’ 
neighboring base (G = U > C =A) (Lehmann and Bass, 2000).  These flanking base 
preferences have been consistently reinforced as additional ADAR editing targets 
have been identified. 
 Targets of ADAR editing such as those discussed above fulfill these 
substrate criteria through local or distant, cis or trans RNA sequences.  For ADAR 
editing within coding regions, complementary sequence in an adjacent intron 
often provides a source of base pairing for duplex formation (Herb et al., 1996; 
Higuchi et al., 1993).  Transcript 3’ UTRs frequently contain considerable 
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secondary structure, providing appropriate dsRNA for ADAR editing.  In 
addition, duplicate, inverted Alu elements common in non-coding RNA 
sequences can hybridize into long dsRNA duplexes that support editing 
(Athanasiadis et al., 2004; Kawahara and Nishikura, 2006; Kim et al., 2004; 
Levanon et al., 2004).  Analogous structures are found in the double-stranded 
replication intermediates of many RNA viruses, as well as pre-miRNA 
transcripts, some of which have recently been described as ADAR substrates 
(Blow et al., 2006; Kawahara et al., 2007; Luciano et al., 2004; Yang et al., 2006b).  
Subtle differences within these common structures and sequences can influence 
editing efficiency, resulting in varied proportions of edited and unedited 
transcripts for a given target site.  Taken together, the specific yet flexible 
substrate restrictions and variable frequency of A-to-I editing allow for 




 1.3.  Polynucleotide Cytidine Deaminases: The AID/APOBEC enzymes 
 The AID/APOBEC enzymes also perform base modification editing on 
polynucleotide substrates.  However, unlike the ADARs, AID/APOBEC family 
members act on cytidine residues, which they deaminate to form uridine.  This 
editing activity is not limited to RNA; most AID/APOBEC enzymes deaminate 
single-stranded DNA as their primary substrate.  Understanding APOBEC RNA 
editing is best achieved with a comprehensive background of the entire enzyme 
family (including those members that act on DNA), which is presented here. 
Though the ADAR gene family appears to be present in all metazoans (Jin 
et al., 2009), the evolutionarily younger AID/APOBEC polynucleotide cytidine 
deaminases emerged later, in the vertebrate lineage (Conticello et al., 2005). In 
mammals, this gene family includes Activation-induced cytidine deaminase 
(AID), Apolipoprotein B mRNA Editing Catalytic polypeptide 1 (APOBEC1), 
APOBEC2, APOBEC3 and the computationally predicted APOBEC4.  
Additionally, in primates, the APOBEC3 gene has undergone considerable 
expansion; genes in this subfamily are designated alphabetically APOBEC3A-3H.  
AID and APOBEC2 are the oldest members of the gene family, with the 
appearance of APOBEC1 and APOBEC3 occurring significantly later in 
mammalian evolution (Conticello et al., 2005). In primates, members of the 
AID/APOBEC gene family have undergone rapid evolution and notably strong 
positive selection (Sawyer et al., 2004), likely due to functions for many of these 
enzymes in host defense. 
 All AID/APOBEC proteins contain at least one characteristic zinc-
dependent deaminase domain (Jarmuz et al., 2002; Mian et al., 1998; Wedekind et 
al., 2003).  The active site includes three critical residues (2 cysteines, 1 histidine) 
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that coordinate zinc to activate a water molecule for the hydrolytic deamination 
of cytidine.  An additional conserved glutamic acid residue participates in the 
transfer of a water-derived proton to the leaving imino group of the cytidine ring 
(Smith, 2009).  The catalytic protein motif and mechanism are similar to those of 
bacterial cytidine deaminases that act on mononucleotide substrates 
(Navaratnam et al., 1995).  Most AID/APOBEC proteins contain a single zinc-
dependent deaminase motif, though several of the APOBEC3 enzymes (murine 
APOBEC3, primate APOBEC3B, APOBEC3DE, APOBEC3F, APOBEC3G) contain 
two in distinct domains.  In both APOBEC3F and APOBEC3G, only one of the 
two predicted active sites demonstrates catalytic activity (Haché et al., 2005).  
 The AID/APOBEC cytidine deaminases contribute to diverse biological 
processes, many of which are involved in host defense functions.  AID 
introduces DNA mutations at the immunoglobulin (Ig) locus, which is critical in 
establishing the genetic diversity required for an effective humoral immune 
response.  APOBEC3 enzymes edit retroviral target sequences and thereby 
provide a potent innate defense that can mutate and cripple viral genomes.  In 
addition, APOBEC1 edits the apoB mRNA transcript, mediating the tissue-
specific regulation of apolipoprotein isoforms important in dietary lipid 
absorption. Though each of these processes shares a common feature of cytidine 
to uridine conversion, the physiological contexts and outcomes vary widely. 
1.3.1.  AID - Editing for Antibody Diversification 
AID is a central mediator of the adaptive immune response, driving 
antibody diversification in response to antigenic challenge through two distinct 
processes: somatic hypermutation (SHM) and class switch recombination (CSR).  
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In SHM (Figure 1.3A), point mutations are introduced within the V(D)J regions 
of rearranged Ig loci, thereby altering the antigen binding properties of the 
encoded Ig.  SHM occurs in germinal center B cells and those B cells that acquire 
improved antigen binding affinity are positively selected for survival.  During 
this “affinity maturation,” the Ig variable regions accumulate additional 
mutations and the activated B cells are thereby optimized for a highly specific 
and potent adaptive immune response.  As these modifications are fixed in 
somatic B cell genomes, they are maintained in clonal expansion and subsequent 
memory responses.  In CSR (Figure 1.3B), a region specific recombination 
reaction replaces the primary constant region (Cμ) with a downstream constant 
region (Cγ , Cε , or Cα ). Constant regions code for the Fc portions of antibody 
molecules; recombination between these regions changes the isotype and endows 
the antibody protein with different effector properties.  This genomic and 
functional flexibility allows for an antigen-appropriate response in many 
different infection contexts.  Both of these processes are initiated by AID cytidine 
deamination within the Ig locus. 
Initially identified in a subtractive hybridization screen comparing resting 
B cells and B cells stimulated to undergo CSR (Muramatsu et al., 1999), AID acts 
on cytidine residues in single-stranded DNA (Chaudhuri et al., 2003; Dickerson 
et al., 2003; Pham et al., 2003).  In germinal center B cells, transcription at the Ig 
locus separates the genomic DNA duplex, thereby generating a single-stranded 
substrate for AID deamination.  In SHM, AID activity introduces U:G 
mismatches within rearranged Ig V(D)J gene segments.  The cellular DNA repair 
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Figure 1.3. AID drives antibody diversity through two distinct mechanisms.  
(A) In SHM, AID deaminates cytidines within the variable region of Ig loci.  
Genomic deoxyuridine residues are then resolved by two pathways.  Uridine is 
read as thymidine by replication machinery, leading to transition mutations.  
Alternatively, UNG excises the edited base, which is followed by abasic site 
processing via base excision repair and mismatch repair enzymes, leading to 
transversion mutations.  (B) In CSR, AID deaminates cytidines within Ig switch 
(S) regions, leading to double strand breaks.  Recombination replaces the primary 
constant switch region (C ) with one of several downstream constant regions 
(C  , C  , or C ), altering the effector properties of the encoded antibody.  In this 
representation, the primary C  region is replaced with a C 1 region, thereby 
causing a switch from the IgM to the IgG 1 isotype. 
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deoxyuridines leads to the transition and transversion point mutations of B cell 
affinity maturation.  In CSR, AID deaminates cytidines within repetitive 
sequences between the variable and constant regions of Ig gene segments. This 
editing event (and corresponding DNA breaks) initiates the region-specific 
recombination reaction that results in Ig constant region isotype switch.  
 AID is necessary for both SHM and CSR; these processes are completely 
absent in aicda-/- (AID knockout) mice (Muramatsu et al., 2000).  This functional 
dependence is also observed in humans with Hyper-IgM syndrome, an 
autosomal recessive immunodeficiency characterized by the absence of CSR with 
corresponding elevated serum levels of IgM, the lack of SHM, lymph node 
hyperplasia, and increased susceptibility to infection by encapsulated bacteria.  
The Type II variant of Hyper-IgM syndrome is caused by mutations in the AID 
gene (Revy et al., 2000).  Further evidence for AID’s central role in SHM and CSR 
is provided by experiments demonstrating that exogenous AID expression is 
necessary and sufficient to induce both processes in hybridoma cell lines (Martin 
et al., 2002) and fibroblasts (Okazaki et al., 2002).   
Deficiencies in DNA repair components also affect SHM and CSR.  As a 
result of cytidine deamination, AID generates U:G mismatches, which are 
typically resolved by Uracil DNA Glycosylase (UNG), the primary effector of 
uracil removal in base excision repair.  While UNG-deficient animals acquire Ig 
locus mutations at rates comparable to wild-type controls , the spectra of 
mutations are dramatically different, with a strong bias towards G-to-A and C-
to-T events (Rada et al., 2002).  Ig class-switching is also dramatically reduced.  
Once again, a human analogue is evident in Type V Hyper-IgM syndrome, 
which is associated with mutations UNG gene mutations (Imai et al., 2003; Lee et 
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al., 2005).  Several other DNA repair factors, including MSH2 (Ehrenstein and 
Neuberger, 1999; Rada et al., 1998), MSH6 (Martomo et al., 2004; Martomo et al., 
2005), DNA polymerase η and exonuclease 1 have also been implicated in SHM 
and/or CSR, further underscoring the shared contributions of AID cytidine 
deamination and DNA repair processes in shaping the antibody repertoire. 
As a mutator of genomic DNA, AID must be tightly regulated in germinal 
center B cells.  Though AID can be observed throughout the cell (Ito et al., 2004), 
it is sequestered in the cytoplasm away from genomic DNA by active nuclear 
export (Brar et al., 2004) and cytoplasmic retention mechanisms (Patenaude et al., 
2009).  Conformational changes in an atypical nuclear localization signal allow 
for the active nuclear import of AID (Patenaude et al., 2009).  Once inside the 
nucleus, the mechanism by which AID specifically targets Ig loci remains 
unclear.  Several associated cis chromosomal elements can contribute to AID 
targeting, such as the IgV promoter (Yang et al., 2006a) and Ig heavy chain 3’ 
enhancer sequences (Dunnick et al., 2009), but are not sufficient to explain AID 
specificity (Yang and Schatz, 2007).  Alternatively or additionally, recent 
observations of AID DNA editing at numerous genome locations suggest that 
AID may lack stringent targeting specificity, with an exclusion of high-fidelity 
DNA repair machinery only at the Ig locus allowing for local accumulation of 
mutations (Liu et al., 2008).  Once associated with a ssDNA substrate, AID 
exhibits local sequence preferences for its deaminase activity.  AID preferentially 
deaminates cytidine residues contained in WRC mutation “hot spot” motifs, 
while avoiding activity on cytidines in SYC “cold spot” motifs (Beale et al., 2004; 
Pham et al., 2003).  Similar preferences for neighboring nucleotides have also 
been described for related cytidine deaminases such as APOBEC3G and 
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APOBEC3F (Beale et al., 2004; Harris et al., 2003; Mangeat et al., 2003; Zennou 
and Bieniasz, 2006; Zhang et al., 2003).         
Despite benefits in host defense, the risk of off-target genomic DNA 
editing is significant.  In the context of CSR, it is thought that AID deamination 
(together with UNG activity) generates coupled DNA breaks at the Ig locus. 
Most of these are appropriately repaired, leading to deletional recombination.  
However, occasionally the breaks may be erroneously resolved, giving rise to 
chromosomal translocations. The partner loci for such rearrangements can be 
either genomic sites that can serve as infrequent off-site targets for AID 
(including many proto-oncogenes (Liu et al., 2008; Robbiani et al., 2008)), or 
hypersensitive sites susceptible due to structure (e.g. cruciform DNA at the bcl-2 
locus (Raghavan et al., 2004)) or function (e.g. enhancer elements).  Incorrect 
break resolution can be caused by deficiencies of DNA repair factors (Ramiro et 
al., 2006) or lack of Ig locus CSR targeting elements (Wakae et al., 2006).  
Oncogenic events represent an infrequent but deleterious outcome of 
dysregulated and/or mistargeted DNA editing.  However, in the case of AID, 
the benefit of antibody diversification to host defense generally outweighs these 
consequences of off-target mutation. 
1.3.2.  APOBEC3 Enzymes - Innate Defense Against Retroviruses 
 Initially identified by bioinformatic sequence analysis (Jarmuz et al., 2002), 
the APOBEC3 proteins did not have an obvious function upon first examination.  
Though recognized as polynucleotide cytidine deaminases with likely RNA 
and/or DNA editing activity, their targets were unknown.  However, initially 
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unrelated work in HIV biology soon revealed the potent effects of the APOBEC3 
enzymes on retroviral infection. 
As a complex lentivirus, HIV is built from a genome containing the 
fundamental retroviral genes gag, pol and env, as well as several accessory genes 
that enhance viral infectivity (Malim and Emerman, 2008).  Most of these 
accessory genes were successfully characterized relatively soon after their 
identification.  However, a mechanistic function for virion infectivity factor (Vif) 
remained elusive.  It was observed that ∆vif HIV infection is essentially 
unhindered in certain cell lines (so-called “permissive cells”) yet dramatically 
diminished in other cell lines (“non-permissive cells”) that otherwise support 
productive infection with wild-type HIV (Gabuzda et al., 1992);von Schwedler, 
1993, p05754}.  Heterokaryon studies suggested that the non-permissive cells 
expressed an endogenous viral restriction factor that was apparently obstructed 
by Vif (Madani and Kabat, 1998; Simon et al., 1998).  A subtractive cDNA screen 
performed by Sheehy and colleagues identified this cellular restriction factor as 
CEM15 (Sheehy et al., 2002), also known as APOBEC3G. 
APOBEC3G’s place in the cytidine deaminase family provided clues as to 
how it might function to restrict ∆vif HIV infection.  A torrent of work from 
various groups demonstrated that APOBEC3G restricts HIV by inducing 
hypermutation in newly reverse-transcribed viral cDNA (Figure 1.4) (Harris et 
al., 2003; Lecossier et al., 2003).  In non-permissive cells infected with ∆vif HIV, 
APOBEC3G associates with viral RNA (Khan et al., 2005; Svarovskaia et al., 2004) 
and/or the nucleocapsid domain of Gag (Schäfer et al., 2004), which package the 
enzyme into newly assembled virions.  Nascent viral particles then carry and 
deliver APOBEC3G to newly infected cells, in which the cytidine deaminase 
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Figure 1.4. APOBEC3G restricts HIV infection.  In the context of wild-type 
HIV infection, HIV Vif binds cellular APOBEC3G and recruits a cullin5-
elongin B/C-Rbx ubiquitin ligase complex.  APOBEC3G is polyubiquitylated 
and targeted for degradation in the proteasome.  In the absence of HIV Vif, 
intact APOBEC3G packages with nascent virus particles and is delivered to 
newly infected cells.  Upon reverse transcription, APOBEC3G edits newly 
synthesized (-) strand viral cDNA.  Edited retrotranscripts are degraded or 
integrated as hypermutated proviruses.
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remains associated with the retroviral replication machinery.  Upon reverse 
transcription and following activation by retroviral RNAseH activity (Soros et al., 
2007), APOBEC3G actively deaminates along the retroviral (–)-strand cDNA, 
introducing C-to-U changes through the viral retrogenome.   Most hypermutated 
(–)-strand cDNAs do not proceed to second-strand synthesis, though the 
mechanism for their degradation remains unclear.  Those retrotranscripts that do 
progress to integration carry a heavy mutation burden that drastically 
compromises the information content of the retroviral genome and prevents the 
production of functional virus. 
Both CD4+ T cells and macrophages, the principle targets of HIV infection 
in vivo, express high levels of APOBEC3G (Chiu et al., 2005).  HIV establishes 
productive infections in these cell types through the action of Vif, which excludes 
APOBEC3G from packaging virions primarily by mediating its degradation 
(Conticello et al., 2003; Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; 
Stopak et al., 2003).  In the infected cell, Vif binds APOBEG3G and recruits a 
cullin5-elongin B/C-Rbx ubiquitin ligase complex (Yu et al., 2003) (Kobayashi et 
al., 2005).  APOBEC3G is thereby targeted for ubiquitylation and subsequent 
degradation by the proteasome.  This process allows for the production of 
virions unfettered by packaged APOBEC3G and corresponding hypermutation.  
The Vif/APOBEC3G interaction is precise and species-specific; HIV Vif inhibits 
APOBEC3G from human but not African Green Monkey (AGM), while SIV-
AGM Vif inhibits AGM APOBEC3G, but not human (Mariani et al., 2003).  This 
specificity maps to a single amino acid at position 128 in APOBEC3G (Asp in 
human, Lys in AGM) (Bogerd et al., 2004; Mangeat et al., 2004; Schröfelbauer et 
al., 2006).  Such exacting requirements for association offer a perspective on the 
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powerful selective pressures exhibited by this host-pathogen relationship.  In 
fact, phylogenetic analysis demonstrates that the APOBEC3 subfamily has been 
under markedly strong positive selection throughout primate evolution (Sawyer 
et al., 2004; Zhang and Webb, 2004).  It appears that the sole function of Vif is to 
act as a viral countermeasure against APOBEC3G and related family members.  
The evolutionary pressure to devote such a significant portion of the remarkably 
efficient HIV genome to this purpose illustrates the considerable impact this gene 
family can have on host defense. 
The antiviral activity of the polynucleotide cytidine deaminases is not 
limited to APOBEC3G, nor is it directed solely against HIV.  Aside from 
APOBEC3G, additional family members APOBEC3B and APOBEC3F can also 
restrict HIV replication (reviewed in Rosenberg and Papavasiliou, 2007).  
Interestingly, APOBEC3B cannot be suppressed by Vif (Bishop et al., 2004; 
Doehle et al., 2005).  However, this may not be relevant in vivo, as only 
APOBEC3G and APOBEC3F are expressed by CD4+ T cells and macrophages.  
Indeed, viral sequence analysis of HIV patient isolates reveals mutation patterns 
consistent with APOBEC3G and APOBEC3F activity (Simon et al., 2005).  
Apart from HIV, it seems that most retroviruses are somewhat susceptible 
to members of the APOBEC3 subfamily; Murine leukemia virus, Equine 
infectious anemia virus, foamy retroviruses and even HBV can be restricted by 
different APOBEC3 deaminases (reviewed in Rosenberg and Papavasiliou, 2007).  
Though not a true retrovirus, HBV replicates its partially double-stranded DNA 
genome by a reverse transcription mechanism (Ganem, 1996), which represents a 
likely target for these deaminases.  However, reverse transcription may not be a 
requirement for susceptibility to all APOBEC3 subfamily members; APOBEC3A 
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can dramatically inhibit replication of adeno-associated virus (AAV), a small 
single-stranded DNA parvovirus that replicates via the host cell polymerase 
machinery (Chen et al., 2006).  It remains to be seen if AAV represents a unique 
exception or if APOBEC3 subfamily members exhibit broad antiviral activity 
against diverse non-retroviruses. 
The suppressive activity of the APOBEC3 proteins is not limited to 
exogenous retroviruses; several family members have also been demonstrated to 
restrict a variety of endogenous retroelements.  Such host-encoded retroelements 
constitute significant portions of mammalian genomes and include the long 
terminal repeat  (LTR)-containing endogenous retroviruses (ERVs), as well as 
non-LTR sequences such as long interspersed nuclear element -1(LINE-1).  Many 
of the APOBEC3 deaminases can suppress retrotransposition of ERVs (Esnault et 
al., 2005) and LINE-1 elements (Muckenfuss et al., 2006).  Though it remains 
unclear if the precise mechanism by which APOBEC3 proteins inhibit 
endogenous retroelements is identical to that employed in exogenous viral 
restriction, both appear to be significant targets for this defense system. 
As the existence of functionally active ERVs in humans remains uncertain, 
the physiological relevance of APOBEC3 subfamily activity against these host-
encoded sequences in vivo is not immediately apparent.  Perhaps retroelement 
inhibition represents an “original” function of the APOBEC3 proteins; activity 
against exogenous lentiviruses may have been co-opted later in the evolutionary 
history of this gene family.  Indeed, despite dramatic rates of positive selection 
throughout primate evolution, the apparent selective pressures on the APOBEC3 
genes predate the emergence of modern primate lentiviruses by millions of years 
(Sawyer et al., 2004; Zhang and Webb, 2004).  In addition, the evolutionary 
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expansion of the APOBEC3 family correlates with a dramatic decrease of 
endogenous retroelement activity in primate genomes as compared to rodents 
(Waterston et al., 2002).  Thus, the APOBEC3 proteins may represent an ancient 
defense system for protecting genome integrity, be it from actively mobile 
endogenous retroelements or the primitive retroviruses from which they 
evolved. 
1.3.3.  APOBEC2 and APOBEC4: Orphan Cytidine Deaminases 
 Along with AID, APOBEC2 is one of the oldest members of the 
polynucleotide cytidine deaminase gene family (Conticello et al., 2005).  
However, despite considerable sequence homology to other well-characterized 
AID/APOBEC proteins, the molecular and physiological functions of APOBEC2 
remain largely unknown.  Though initially predicted to act as a DNA/RNA 
editor (Liao et al., 1999), APOBEC2 does not deaminate polynucleotide substrates 
in vitro (Liao et al., 1999; Mikl et al., 2005).  Additional biochemical 
characterizations have generated conflicting data, with some experiments 
demonstrating free mononucleotide deaminase activity (Anant et al., 2001b; Liao 
et al., 1999) and others suggesting a catalytically inert protein (Mikl et al., 2005).  
The APOBEC2 crystal structure revealed a homotetrameric polypeptide complex 
with active sites accessible to DNA and RNA (Prochnow et al., 2007), but while 
useful for modeling the structures of other AID/APOBEC family members, it has 
not elucidated APOBEC2 function.  APOBEC2 is present exclusively in skeletal 
and cardiac muscle, where it is expressed at high levels (Liao et al., 1999).  Upon 
initial examination, apobec2-/- mice were reported to be apparently normal and 
without phenotypic defects (Mikl et al., 2005).  However, more thorough 
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investigation has recently revealed that APOBEC2 functions in muscle 
differentiation and maintenance (Sato et al., 2009).  APOBEC2 is present at higher 
levels in slow-twitch (high aerobic potential) muscle fibers and apobec2-/- mice 
have dramatically higher slow-twitch:fast-twitch fiber ratios than wild-type 
controls.  The molecular mechanism for these physiological differences remain 
unclear; if APOBEC2 edits RNA or DNA substrates, the identification of its target 
sequences should provide considerable insight as to its role in muscle 
development and function. 
 APOBEC4 is another “orphan” member of the polynucleotide cytidine 
deaminase gene family.  Identified by computational sequence analysis, the 
APOBEC4 gene contains a characteristic zinc-dependent deaminase domain and 
bears significant homology to other family members (Rogozin et al., 2005).  
However, it’s catalytic potential, substrate specificity (DNA/RNA) and possible 
sequence preferences remain unknown.  APOBEC4 is predominantly expressed 
in testis, where its physiological function has not been identified.  As with 
APOBEC2, the identification of editing targets for APOBEC4 in testis should 
greatly aid its biological characterization. 
1.3.4. APOBEC1 – An RNA Editing Cytidine Deaminase  
APOBEC1 was the first polynucleotide cytidine deaminase discovered in 
mammals, and is named for its editing substrate, apolipoprotein B (apoB) mRNA 
(Figure 1.5).  The apoB protein product exists as two related forms, both 
important in lipid metabolism (Chan, 1992).  The full-length isoform, apoB-100, is 
produced by the liver and forms the principle lipoprotein component of LDL 


















Figure 1.5. apoB mRNA editing by APOBEC1. apoB-100 and apoB-48 are 
derived from identical primary mRNA transcripts.  In the absence of 
APOBEC1 editing, full-length apoB-100 is synthesized and incorporated into 
LDL lipoprotein particles.  In small intestinal enterocytes, APOBEC1 site-
specifically deaminates a cytidine in the apoB mRNA, thereby converting a 
glutamine codon (CAA) to a STOP codon (UAA).  Upon translation, the 
truncated apoB-48 isoform is produced and incorporated into chylomicrons.
Adapted from Stryer, L. Biochemistry. 5th edition, 2002. 
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The shorter apoB-48 isoform (designated as 48% of full-length apoB-100) is 
produced by the small intestine, in which it is essential for chylomicron 
formation and the absorption and transport of dietary lipid.  ApoB is essential for 
mammalian life and development; homozygous apoB deletion mutants are 
embryonic lethal in mice (Farese et al., 1995).  Both isoforms of apoB share 
identical primary transcripts and are not regulated by differential splicing or 
post-translational processing.  In the small intestine, cytidine 6666 of the apoB 
mRNA is deaminated to uridine, thereby converting a glutamine codon (CAA) to 
a stop codon (UAA) and terminating elongation upon translation of apoB-48 
(Chen et al., 1987; Powell et al., 1987).  This site-specific mRNA modification is 
mediated by a multiprotein “editosome” complex, the catalytic component of 
which is APOBEC1 (Teng et al., 1993). 
 APOBEC1 is the only member of the AID/APOBEC family demonstrated 
to edit mRNA in vivo.  The APOBEC1 protein contains a single zinc-dependent 
cytidine deaminase domain along with an RNA binding domain (MacGinnitie et 
al., 1995).  In addition, the enzyme contains C-terminal protein-protein 
interaction motifs (Oka et al., 1997), which are thought to be involved in editing 
complex assembly.  Evolutionarily, APOBEC1 is a relatively recent addition to 
the AID/APOBEC gene family; while AID and APOBEC2 are found from jawed 
fishes onward, APOBEC1 is present only in mammals (including marsupials) 
(Conticello et al., 2005).  In humans, APOBEC1 expression appears to be 
exclusive to the small intestine (Lau et al., 1994).  In many other mammals, 
however, while the small intestine remains the principal site of expression and 
apoB mRNA editing (Greeve et al., 1993), APOBEC1 can be found at additional 
tissue sites such as liver, spleen and lymph node (Hirano et al., 1997; Nakamuta 
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et al., 1995).  apobec1-/- mice, though apparently healthy and fertile, do not edit 
apoB mRNA and have no apoB-48 in their serum (Hirano et al., 1996; Morrison et 
al., 1996). 
 The mechanism of apoB mRNA editing by APOBEC1 has been fairly well 
characterized.  Though APOBEC1 shuttles between the cytoplasm and the 
nucleus (Bennett et al., 2006; Yang and Smith, 1997), apoB mRNA editing is an 
intranuclear event (Lau et al., 1991).  Editing takes place either coincident with or 
immediately after transcript splicing and polyadenylation.  APOBEC1 alone is 
not sufficient to recognize and deaminate apoB mRNA.  Editing requires a large, 
multiprotein editosome complex, the minimal functional components of which 
are APOBEC1 and APOBEC1 Complementation Factor (ACF), an RNA binding 
protein.  Purified ACF and APOBEC1 proteins are necessary and sufficient to 
support apoB editing in vitro. 
 ACF is a 64-kilodalton protein that was initially purified from baboon 
kidney extracts as an activity that functionally complements apoB mRNA editing 
by APOBEC1 (Mehta et al., 1996).  The domain organization of ACF consists of 
three N-terminal RNA recognition motifs (RRMs), an arginine-glycine rich 
region, and a C-terminal dsRBM (Blanc et al., 2001a; Mehta et al., 2000).  The 
tandem RRMs can form a large RNA binding surface capable of binding specific 
RNA sequences (Maris et al., 2005) .  ACF also contains a nuclear localization 
signal that mediates its trafficking between the cytoplasm and nucleus (Blanc et 
al., 2003).  This process is modulated by phosphorylation at multiple residues in 
ACF and contributes to the regulation of apoB mRNA editing in rodent 
hepatocytes (Lehmann et al., 2007; Lehmann et al., 2006).  The ACF gene is 
alternatively spliced to generate at least 4 protein isoforms, which have different 
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capacities to support apoB editing (Dance et al., 2002; Sowden et al., 2004).  
Interestingly, deletions of ACF are embryonic lethal in mice, indicating that this 
RNA-binding protein serves additional functions beyond apoB mRNA editing 
(Blanc et al., 2005). 
 Though APOBEC1 and ACF constitute the minimal functional unit of 
apoB mRNA editing, the in vivo editosome is likely more complex.  Multiple 
proteins that interact with APOBEC1, ACF, and/or RNA have been identified, 
several of which can modulate apoB editing.  Glycine-arginine-tyrosine-rich 
RNA binding protein (GRY-RBP) is an hnRNP family member with significant 
homology to ACF, especially within its three similar RRM domains (Blanc et al., 
2001b; Lau et al., 2001a).  GRY-RBP inhibits apoB mRNA editing, likely through 
the binding and sequestration of ACF.  CUG triplet repeat RNA binding protein 
2 (CUGBP2) also contains RRMs, interacts with ACF and apoB mRNA, and 
inhibits APOBEC1 editing (Anant et al., 2001a).  Other proteins that interact with 
APOBEC1 and enhance apoB mRNA editing have been described, such as 
APOBEC-1 Binding Protein-1 (ABBP-1) (Lau et al., 1997) and ABBP-2 (Lau et al., 
2001b).  The functional significance of these and additional yet-to-be-identified 
editosome component and associating proteins in vivo remain poorly 
understood.  However, observations of APOBEC1 and/or ACF interacting 
factors supports a model in which apoB mRNA editing is carried out by a 
dynamic multimolecular complex with various regulatory components that 
modulate the reaction.   
 The APOBEC1 editing site in apoB mRNA is specified primarily by 
APOBEC1/ACF editosome recognition of local sequence elements in the apoB 
transcript.  As an RNA binding protein, APOBEC1 exhibits a strong preference 
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for RNA sequences rich in A and U nucleotides (Anant et al., 1995; Navaratnam 
et al., 1995).  Consistent with this observation, the transcript region containing 
the apoB editing site has a notably high AU content (70% A/U in a 101 nt 
window centered on the target cytidine).  However, general AU content is not 
sufficient to convey precise targeting; specific sequence motifs are also required.  
The apoB mRNA contains an 11 nt “mooring sequence” (UGAUCAGUAUA) 5 nt 
downstream (3’) of the edited cytidine that serves as the principal determinant 
for apoB editosome targeting (Shah et al., 1991).  Introducing mutations to the 
mooring sequence diminishes or eliminates editing, depending on which 
residues are altered.  Furthermore, the experimental insertion of a mooring 
sequence downstream of a cytidine in heterologous AU-rich RNA is sufficient to 
induce editing by the APOBEC1/ACF complex, albeit at lower efficiency than 
observed in apoB RNA (Backus and Smith, 1991; Driscoll et al., 1993).  Additional 
cis-acting elements in the apoB mRNA include a 5’ AU-rich efficiency sequence 
and a 3’sequence that modulates editing frequency.  However, the minimal 
sequence of the apoB mRNA required for editing includes only the editing site, a 
short portion of the 5’ efficiency sequence, and the mooring sequence along with 
a spacer element to separate it appropriately from the target cytidine (Backus 
and Smith, 1992; Shah et al., 1991).  
 The sequence containing the editing site in apoB mRNA adopts a flexible 
imperfect hairpin secondary structure, which was phylogenetically predicted 
(Hersberger et al., 1999) and later confirmed by NMR spectroscopy (Maris et al., 
2005).  The target cytidine lies at the 5’ portion of the hairpin loop, with the 
mooring sequence starting in the 3’ portion of the loop and continuing into the 
stem duplex.  In a current mechanistic model for apoB mRNA editing (Maris and 
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Allain, 2009), editosome-associated ACF recognizes and binds the apoB mooring 
sequence through its RRMs (Dance et al., 2002; Lellek et al., 2000; Mehta et al., 
2000) and mediates the melting of the stem-loop structure (Maris et al., 2005), 
thereby generating a single-stranded RNA substrate amenable to APOBEC1 
editing.  The spacer element and editosome architecture are thought to ensure 
that the target cytidine is properly positioned in the cytidine deaminase active 
site.  Following the editing reaction, the editosome remains associated with the 
apoB mRNA to facilitate its export from the nucleus and/or protect the edited 
transcript, which now contains a premature termination codon, from nonsense 
mediated decay (Chester et al., 2003).      
 Following the characterization of APOBEC1 as an RNA cytidine 
deaminase, numerous studies have investigated the possibility of additional 
functions and targets for the enzyme beyond its role in apoB editing.  Attempts 
to identify additional mRNA editing targets have not yield many physiologically 
relevant substrates.  Transgene-mediated hepatic overexpression of APOBEC1 
causes editing of the eukaryotic translation initiation factor 4 (Eif4g2, also 
referred to as NAT1) mRNA (Yamanaka et al., 1997), but little evidence supports 
Eif4g2 as a target of APOBEC1 at endogenous levels.  C-to-U editing in 
neurofibromatosis 1 (NF1) mRNA has been observed in peripheral nerve-sheath 
tumors and introduces a stop codon within the NF1 coding sequence 
(Mukhopadhyay et al., 2002; Skuse et al., 1996).  The editing site is adjacent to a 
mooring sequence-like motif and likely represents a genuine APOBEC1 editing 
event.  However, the editing observed was at relatively low levels and only 
occurred in a subset of patient samples.  Thus, though NF1 may represent an 
37
 
important APOBEC1 target in certain neurofibromatosis type I tumors, it likely 
does not represent a physiological target of editing in healthy, steady state tissue. 
 Though additional mRNA editing substrates have not been identified, 
APOBEC1 participates in several other biological processes independent of its 
deaminase activity.  As an RNA-binding protein, APOBEC1 can bind to the AU-
rich 3’ UTRs of several transcripts to modulate their stability.  This type of 
regulatory mechanism has been observed in APOBEC1 stabilization of the 
Cyclooxygenase-2 (COX-2) (Anant et al., 2004), c-myc (Anant and Davidson, 
2000), and Cholesterol 7α-Hydroxylase (Cyp7a1) (Xie et al., 2009) mRNAs.  
Dysregulation of Cyp7a1 may be responsible for the increased susceptibility to 
gallstone disease of apobec1-/- mice.  Such editing-independent functions may 
imply a broader biological influence for APOBEC1 than previously assumed.  
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 1.4.  Statement of the Problem 
 Multiple DNA and RNA editing enzymes, including APOBEC1 and AID, 
were identified based on prior observation of specific editing substrates.  For 
AID, the recognition of point mutations in genes encoding antibody variable 
regions prompted a search for the DNA modification enzyme responsible.  
Similarly, the detection of an edited cytidine residue in apoB mRNA led to the 
discovery of APOBEC1.  Though this approach has yielded many findings of 
great significance, it is limited in its potential to detect alternative biological roles 
for these enzymes beyond their initially observed editing substrates. 
Several experimental observations suggest that APOBEC1 may have 
additional RNA editing targets aside from apoB.  First, apobec1-/- phenotypes 
associated with binding and stabilization of transcript 3’ UTRs (Anant and 
Davidson, 2000; Anant et al., 2004; Xie et al., 2009) indicate that APOBEC1 
interacts with many enterocyte mRNAs aside from apoB.  Secondly, in many 
mammals, APOBEC1 is expressed in diverse tissues, including small intestine, 
liver, kidney, muscle and spleen (Nakamuta et al., 1995).  Though transcribed 
and edited in intestine and liver, apoB mRNA is not present in tissues such as 
spleen.  The absence of the apoB mRNA target raises questions as to the function 
of APOBEC1 in these tissues. Experimentation in our laboratory has detected 
APOBEC1 expression in specific immune cell types, including B cells, 
macrophages and dendritic cells.  Furthermore, APOBEC1 expression in immune 
cells is differentially regulated in response to various stimuli (Figure 1.6).  
Finally, APOBEC1 exhibits significant positive selection throughout mammalian 
evolution (Sawyer et al., 2004), even though apoB mRNA editing is dispensable 








































































Figure 1.6.  APOBEC1 mRNA is differentially regulated in immune cells.  (A) 
Bone-marrow derived dendritic cells were stimulated with various TLR ligands 
(LPS, Poly(I:C), CpG oligonucleotides).  GAPDH-normalized APOBEC1 mRNA 
levels were assessed by quantitative real-time PCR.  (B) Splenocytes were 
harvested from C57/BL6 mice and FACSorted for CD11c+CD8+ and CD11c+CD8- 
dendritic cell subsets. GAPDH-normalized APOBEC1 mRNA levels were 
assessed by quantitative real-time PCR.     
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Morrison et al., 1996), additional activities for APOBEC1 might be context-
dependent.  For example, APOBEC1 could function in the immune response to 
infection, as is the case for other AID/APOBEC family members. 
 Does APOBEC1 edit mRNAs other than the apoB transcript?  As 
discussed above, previous attempts to identify additional editing sites by 
empirical and/or computational methods have not expanded the enzyme’s 
target list (Smith et al., 2005).  The likelihood of additional APOBEC1 RNA 
targets, as well as the discovery of other polynucleotide cytidine deaminases 
without known substrates (e.g. APOBEC2, APOBEC4), demands a novel 
approach to identify DNA and RNA editing events.   
A bona fide RNA editing event can be defined as a discrepancy in the 
sequence of genomic DNA and RNA derived from the same cell or tissue sample.  
Similarly, an APOBEC1-dependent editing event would be present in samples 
derived from wild-type mice but absent from samples derived from congenic 
apobec1-/- mice.  In essence, single nucleotide differences between two such RNA 
pools would represent APOBEC1 editing targets.  However, without prior 
knowledge of which transcripts and sequences to examine, detecting such 
differences presents a challenge.  Though biochemical techniques to detect 
nucleotide variations between pools of DNA (and RNA, by reverse transcription 
to cDNA) have been developed (Pan and Weissman, 2002), they are not 
sufficiently sensitive or practical for application at the scale of whole eukaryotic 
transcriptomes. 
The recent development of ultra-high throughput sequencing technologies 
provides powerful tools for more comprehensive investigation of RNA editing.  
One recent study used target capture and deep sequencing to detect A-to-I 
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editing in numerous computationally predicted RNA targets (Li et al., 2009b).  
Whole transcriptome sequencing (RNA-Seq) represents another promising 
option for broad characterization of RNA editing.  Though RNA-Seq is 
frequently used for transcriptome mapping and quantification (Mortazavi et al., 
2008; Nagalakshmi et al., 2008; Sultan et al., 2008), it has also been successfully 
applied to the analysis of single nucleotide polymorphisms (SNPs) in expressed 
genes (Chepelev et al., 2009; Heap et al., 2010).  In considering a strategy for the 
discovery of APOBEC1 targets, I reasoned that given sufficient transcript 
coverage and read depth, the single nucleotide resolution of RNA-Seq could be 
used to identify candidate RNA editing sites throughout a transcriptome. 
 This thesis presents the development of an RNA-Seq method for the 
identification of mRNA editing events on a transcriptome-wide scale and its 
application to the discovery of APOBEC1 editing targets in small intestine 
enterocytes.  This comparative screening approach involves ultra-high 
throughput sequencing of wild-type and apobec1-/- transcriptomes to identify 
APOBEC1-specific candidate editing sites.  The small intestine provides an ideal 
experimental system for the development and validation of this technique, with 
apoB serving as an exceptional internal positive control.  In addition to successful 
detection of the well-characterized apoB site, more than 30 previously 
undescribed editing events were identified and validated in small intestine 
enterocyte mRNA.  Interestingly, these newly recognized editing sits are located 
in the 3’ UTRs of diverse transcripts. These sites share several characteristic 
sequence features, including a downstream (3’) motif similar to the mooring 
sequence in apoB mRNA.  Many of the editing sites are located within transcript 
regions significantly conserved in mammalian evolution, implying possible 
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functional importance.  These findings demonstrate the feasibility and utility of a 
transcriptomics approach to RNA editing studies and substantially expand the 
list of sites that undergo APOBEC1-dependent editing in vivo.  In addition, the 
diverse editing targets identified suggest additional functions for APOBEC1 
beyond its role in apoB-mediated lipid absorption and transport. 
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CHAPTER 2: PILOT STUDY – WHOLE INTESTINE 
2.1.  Experimental Strategy and Design 
 The empirical identification of RNA editing events can be achieved by 
detecting single nucleotide differences in a comparison of edited and unedited 
sequences.  As such, assessing editing for a given mRNA transcript can be 
achieved by standard techniques such as reverse transcription, PCR and 
dideoxynucleotide Sanger sequencing.  However, these techniques require prior 
knowledge of which transcript(s) to examine for editing.  While the identification 
of unknown RNA editing events throughout a transcriptome raises numerous 
technical and analytical challenges, the basis for their recognition remains 
essentially the same: given a set of sequences exposed to editing activity and a 
corresponding set of sequences not exposed to editing activity, nucleotide 
variations are indicative of editing.  Therefore, the experimental approach 
presented here begins with ultra-high throughput sequencing of whole 
transcriptomes isolated from wild-type and deaminase (editing enzyme)-
deficient cells or tissues.  Next, computational sequence analysis is used to 
identify single nucleotide variants specific to the wild-type transcriptome.  
Finally, with a defined list of candidates, RNA editing is validated by standard 
molecular biological techniques.  This analysis workflow is presented in Figure 
2.1.  The details and rationale for this experimental strategy and its validation in 
mouse small intestine are described below. 
2.1.1.  Whole Transcriptome Sequencing 
 Recent technological advances now allow for the practical sequencing of 



































Figure 2.1.  Comparative RNA-Seq screening strategy for the identification 
of APOBEC1 mRNA editing targets.
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of cellular RNA via cDNA (RNA-Seq) is frequently used for gene expression 
profiling, but the nucleotide resolution of sequence data generated by this 
method can also be used to detect single base variants, such as exonic SNPs.  As 
such, it should also be capable of detecting nucleotide variants generated by 
RNA editing. 
 As detailed below, RNA-Seq libraries are prepared by isolating polyA+ 
mRNA, non-specifically fragmenting the mRNA into short (~200 nt) segments, 
and converting these to double-stranded cDNA duplexes containing flanking 
linker sequences.  These linkers are recognized in the ultra-high throughput 
sequencing process, which is performed using the Illumina Genome Analyzer II.  
Sequencing generates tens of millions of short (36 nt) reads per library with an 
error rate of less than 1%.  For each read, output files contain a unique identifier, 
sequence data and Phred-scaled quality scores for each base. 
2.1.2.  Mapping RNA-Seq reads to a reference genome 
 Following ultra-high throughput sequencing, reads are mapped and 
aligned to a reference genome.  Mapping RNA-Seq reads presents a number of 
computational challenges.  First, though sufficient for most transcripts of 
adequate quality (Mortazavi et al., 2008), reads 36 nt in length may not contain 
enough sequence information to map uniquely.  This can present difficulties in 
mapping reads derived from orthologous and/or repetitive transcript regions.  
Secondly, sequencing libraries derived from randomly fragmented mature 
mRNAs will generate a significant proportion of reads spanning exon-exon 
junctions.  Though such reads contain sequence contiguous in a mature, spliced 
mRNA transcript, the separated genomic context of distinct exons effectively 
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divides such sequences to at least two locations in the reference.  Therefore, any 
RNA-Seq mapping algorithm must incorporate a strategy for the alignment of 
exon junction-spanning reads, which can constitute approximately 3-15% of 
mappable reads in a typical short (25 nt - 36 nt) read dataset (Mortazavi et al., 
2008; data not shown).  Finally, and of particular significance for RNA editing 
studies, many reads will contain incorrect base calls as a result of the inherent 
error of ultra-high throughput sequencing.  A mapping strategy should be 
permissive for some read-to-reference mismatches resulting from sequencing 
error or RNA editing.  Editing mismatches can be distinguished from sequencing 
errors in downstream analysis. 
  There are several academic and commercial software packages available 
for alignment of RNA-Seq short read data.  Though many are likely compatible 
with a similar workflow, the “Tuxedo Tools,” TopHat (for mapping RNA-Seq 
reads) (Trapnell et al., 2009) and Bowtie (for aligning reads to reference genome) 
(Langmead et al., 2009) were selected on account of their flexibility and 
efficiency.  Taking into account the challenges described above and the demands 
of detecting nucleotide variations indicative of mRNA editing, the following 
alignment strategy was implemented: 
a. Alignments should allow for mismatches in reads relative to the 
reference genome. 
b. Alignments should be “quality conscious.”  Due to the relatively high 
error rate of ultra high-throughput sequencing and relatively low 
probability of an mRNA editing event, base quality scores should be 
taken into account for mapping and mismatch calling algorithms. 
47
 
c. Alignments should be unique.  As an mRNA editing event is detected 
as a read mismatch to reference, it is imperative that mismatches occur 
only at “real” editing sites and not as a result of sequencing errors.  
Therefore, the mapping algorithm should suppress all reads for which 
an alignment is not “unique”, i.e. it can be satisfactorily mapped to 
more than one location in the genome while still satisfying mismatch 
and quality limits.  Though such an approach will dramatically reduce 
the number of potentially “good” alignments, such stringency ensures 
high confidence in mismatch hits. 
d. Reads spanning exon-exon junctions should be mapped accordingly.  
Different alignment algorithms approach the problem of mapping 
reads derived from mature, spliced mRNAs to genomic reference with 
various strategies; these include alignment to an artificial “splice-ome” 
reference sequence of all predicted exon-exon junctions (Mortazavi et 
al., 2008), and ab initio mapping of reads to junctions predicted by read 
distribution and pileup (Trapnell et al., 2009).  In order to allow for 
read mapping across novel splice junctions not present in annotation 
databases, the TopHat algorithm attempts to identify exon borders 
based on reads derived entirely from individual exons.  Briefly, reads 
are first mapped to the reference genome irrespective of splicing 
information.  Those reads (including junction-spanning reads) that 
cannot be mapped are set aside.  The alignment pattern of mappable 
reads is then used to identify exons and place them within probable 
gene models, which are then used to generate different combinations 
of exon-exon junctional reference sequence.  Next, the previously 
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unmappable reads are aligned against the newly-generated junctional 
reference.  Junctional read alignments are then split accordingly and 
output with genomic coordinates.  This ab initio mapping algorithm 
can also be supplemented with previously characterized gene 
annotations, allowing for alignments to known and novel transcript 
models. 
Finally, all TopHat alignments are output to a single comprehensive Sequence 
Alignment/Map (SAM) file, which is used in downstream mismatch analysis. 
2.1.3.  Identifying read-to-reference mismatches 
Once suitable RNA-Seq alignments are generated, single nucleotide 
mismatches in wild-type reads relative to the reference sequence are identified.  
There are few (if any), software options specifically designed to call mismatches 
generated by RNA editing events.  However, several analysis packages 
incorporate genomic SNP calling algorithms, which can also be implemented for 
RNA mismatch analysis.  Most importantly, as for the alignment step, mismatch 
calling should be “quality conscious” to ensure high confidence in read:reference 
discrepancies. 
The publicly available, open source SAMTools software package 
developed at the Sanger Institute was selected for mismatch analysis (Li et al., 
2009a).  Beginning with a TopHat generated SAM file, SAMTools generates a 
“pileup” file of aligned RNA-Seq reads relative to the reference genome.  Unlike 
the input SAM file, in which entries are organized by individual reads, the 
pileup file contains reads and their qualities on a reference base-by-base scale 
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and a corresponding consensus base call at each position (Figure 2.2).  Thus, for a 
given nucleotide position in the transcriptome, the pileup file includes data on 
the number of reads covering the position, the base content and corresponding 
quality score of each read, the consensus base derived from the aggregate reads 
at the position, and a consensus probability score indicating the likelihood of an 
incorrect consensus base call.  Furthermore, when the base content of reads 
mapped to given a position do not match the reference base, the pileup file 
contains a consensus mismatch base call and corresponding mismatch 
probability score.  The consensus probability score is defined as the Phred-scaled 
probability that the consensus base call is incorrect, while the mismatch 
probability score is defined as the Phred-scaled probability that the consensus 
base call matches the reference base (Li et al., 2008).  Both values are based on 
read depth and read quality scores. 
 In order to generate a starting list of candidate RNA editing sites, 
consensus and mismatch information is used to identify significant single 
nucleotide read:reference mismatches from the wild-type dataset.  However, the 
list of variations may contain large numbers of read:reference mismatches 
unrelated to mRNA editing.  These mismatches may be a result of genomic 
SNPs, sequencing errors, misaligned reads, reverse transcription/amplification 
errors and unrelated mRNA modification processes.  As such, the initial 
variation list must be filtered on several criteria appropriate to RNA editing, 
including error probability, sequence type (exons of known or predicted genes 
only), read:reference mismatch base calls, known SNPs and repetitive elements. 
A particular series of filters will be unique to the mRNA editing enzyme studied; 


















































Read Bases Read Quality Scores
chr1 192830760 T T 66 0 13 ,,.,,,,,,,,,, IIIIIIIIIIIII
chr1 192830761 G R 35 95 14 aaAaaaa,a,a,aa IIIIIIIIIIIIII
chr1 192830762 A A 69 0 14 ,,.,,,,,,,,,,, IIIIIIIIIIIIII
chr1 192830763 A A 69 0 14 ,,.,,,,,,,,,,, IIIIIIIIIIIIII
chr1 192830764 A A 69 0 14 ,,.,,,,,,,,,,, IIIIIIIIIIIIII
chr1 192830765 C C 66 0 13 ,.,,,,,,,,,,, IIIIIIIIIIIII
chr1 192830766 A A 63 0 12 .,,,,,,,,,,, IIIIIIIIIIII
chr1 192830767 G G 63 0 12 .,,,,,,,,,,, IIIIIIIIIIII
chr1 192830768 A A 63 0 12 .,,,,,,,,,,, IIIIIIIIIIII
chr1 192830769 A A 63 0 12 .,,,,,,,,,,, IIIIIIIIIIII
Figure 2.2.  Excerpt from a pileup file.  RNA-Seq read data are represented at 
individual base positions in the reference genome.  This excerpt depicts read 
data for chr1:192830760 – 192830760.  For read bases, periods or commas 
indicate matches to the reference sequence.  Read quality scores are 
represented in ASCII character format; numerical scores are equal to (ASCII 
code) – 33.  A consensus G-to-A mismatch is apparent at chr1:192830761.    
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mismatches.  Though stringent filters could potentially discard genuine RNA 
editing sites, they also minimize the screen’s false detection rate and were 
deemed necessary for a manageable analysis. 
2.1.4.  Identifying specific mRNA editing sites 
 Once read:reference mismatches in the wild-type dataset are identified 
and filtered, specific editing events are distinguished from other variants.  
Mapped and aligned RNA-Seq reads from the deaminase-deficient sample serve 
as a control for this purpose.  Each wild-type mismatch site is compared to the 
corresponding site in the deaminase-deficient pileup dataset; if the deaminase-
deficient alignment also contains the read:reference mismatch, the variant is not 
editing-specific and discarded.  However, if the deaminase-deficient reads (and 
corresponding consensus) do not contain a mismatch, the site is selected as a 
candidate mRNA editing site.  The reliability of this comparison depends on 
sufficient read coverage and base quality in both the wild-type and deaminase-
deficient datasets. 
2.1.5.  Validation of candidate mRNA editing sites 
 With a defined list of candidate sites provided by the RNA-Seq screen, 
mRNA editing can be confirmed using standard techniques.  First, genomic DNA 
from each library is sequenced to rule out heterozygosity.  Next, genomic DNA 
sequences from wild-type and deaminase-deficient samples are compared to rule 
out a SNP.  Wild-type cDNA sequence is compared to wild-type genomic DNA 
sequence to confirm mRNA editing.  Finally, deaminase-deficient cDNA 
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sequence is compared to wild-type cDNA sequence to validate specific 
deaminase activity. 
2.1.6.  Testing the screening method: APOBEC1 in the small intestine 
 Developing a novel experimental approach to the identification of RNA 
editing targets requires technical validation by means of a positive control.  As 
such, the feasibility and utility of the RNA-Seq screen was tested on APOBEC1 
editing in the small intestine.  ApoB mRNA is the only confirmed target of 
APOBEC1 in the intestine.  In wild-type mice, editing of the apoB mRNA is 
efficient; approximately 90-100% of intestinal apoB transcripts are site-
specifically edited from cytidine to uridine (Figure 2.3).  In contrast, no editing is 
detectable in apoB transcripts isolated from apobec1-/- intestine.  Therefore, apoB 
represents an unambiguous positive control for mRNA editing.  If the RNA-Seq 
screening approach is to be useful in identifying unknown, potentially 














Figure 2.3. ApoB mRNA editing in the small intestine.  Sanger sequencing of 
genomic DNA and cDNA derived from jejunal segments of wild-type and 
apobec1-/- mice illustrates APOBEC1-dependent apoB mRNA editing.  Editing 
is site-specific and efficient; near complete C-to-U(T) conversion is apparent in 
the wild-type cDNA chromatogram.  
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2.2.  Experimental Procedures 
 
2.2.1.  Mice 
C57/BL6 wild-type and congenic apobec1-/- mice were used at 6-8 weeks of age.  
Apobec1-/- mice (Hirano et al., 1996) were generously provided by N. Davidson 
(Washington University School of Medicine, St Louis, MO). 
2.2.2.  Preparation of RNA-Seq Libraries 
The RNA-Seq library preparation protocol was adapted from (Mortazavi 
et al., 2008) and Illumina product literature. 
Total RNA was isolated from whole intestine tissue by organic extraction 
with TRI Reagent (Ambion).  The starting total RNA was confirmed to be of high 
quality by Agilent Bioanalyzer 2100 analysis.  PolyA+ mRNA was isolated using 
the MicroPoly(A)Purist Kit (Ambion).  Total RNA was incubated on polyT resin 
at room temperature for 1 hr to ensure maximum binding and recovery of 
polyA+ mRNA.  Following initial polyA+ mRNA enrichment, the procedure was 
repeated with fresh polyT resin to maximize depletion of non-mRNA species.  
Purity and size distribution of enriched polyA+ mRNA was monitored by 
Agilent Bioanalyzer 2100 analysis. 
Following confirmation of quality, the polyA+ mRNA was concentrated by 
ethanol precipitation and resuspended in water to a final concentration of 100 
ng/ul.  Approximately 800 ng of polyA+ mRNA was then non-specifically 
fragmented by supplementing with fragmentation buffer (final composition: 40 
mM Tris acetate, pH 8.2, 100 mM potassium acetate, 30 mM magnesium acetate) 
and incubating at 94ºC for 4 min 30 sec.  Fragmented polyA+ mRNA was then 
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washed and concentrated by ethanol precipitation. The distribution of mRNA 
fragment sizes was evaluated by the Agilent Bioanalyzer 2100. 
First-strand cDNA was prepared using Superscript III Reverse 
Transcriptase (Invitrogen) with random hexamer priming.  The reverse 
transcription reaction was incubated at 51°C for 45 min prior to enzyme 
inactivation at 70°C.   Second-strand synthesis was performed using the 
SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen) and its RNase H, 
E. coli DNA polymerase and E. coli DNA ligase components.  Following the 2 hr 
synthesis reaction, T4 DNA polymerase was added to fill-in offset ends. 
In order to facilitate subsequent linker oligonucleotide ligation, adenine 
overhangs were added to the ds-cDNA by Klenow Fragment (3´→5´ exo–) in the 
presence of 200 mM dATP (incubated at 37°C for 30 min).  Next, Illumina 
sequencing adaptors were ligated to the ds-cDNA duplexes using concentrated 
T4 DNA ligase (New England Biolabs).   
RNA-Seq ultra high-throughput sequencing is most effective with cDNA 
fragments of relatively short (~200 nt) and defined size.  As RNA fragmentation 
can be variable and somewhat heterogeneous, libraries were separated by 
agarose gel electrophoresis and extracted based on DNA size standards.  Though 
sample lanes were not visible due to the small amount of cDNA, alternating 
DNA size marker lanes served as a guide by which to excise gel slices containing 
cDNA duplexes of 200 +/- 25 nt.  Following spin-column gel extraction (Qiagen), 
RNA-Seq libraries were prepared by amplifying (15 cycles PCR) the adaptor-
ligated ds-cDNA with Phusion high-fidelity DNA polymerase (New England 
Biolabs) and Illumina primers (PE 1.0 and PE 2.0) complimentary to portions of 
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the ligated adaptor sequences.  The concentration and purity of final amplified 
RNA-Seq libraries was determined by Nanodrop spectrophotometer and Agilent 
Bioanalyzer 2100. 
2.2.3.  Ultra high-throughput sequencing 
Ultra high-throughput sequencing on the Illumina Genome Analyzer II 
(GAII) was performed with Scott Dewell (Rockefeller University Genomics 
Resource Center) and is detailed in the corresponding Illumina technical 
literature (Illumina, 2008a, b).  A brief summary of the technique as it applies to 
this project appears here. 
RNA-Seq libraries were diluted to concentrations ranging from 4 to 8 pM 
and hybridized to an Illumina GAII flowcell, on which covalently linked 
oligomers (complimentary to the library adapter sequences) capture the ds-
cDNA templates. Libraries were then bridge-amplified onto flowcell-bound 
oligomers and removed by denaturing and washing. Bridged templates were 
polymerase amplified, thereby generating flowcell-bound, sequence-matched 
“clusters.”  Following cluster “clean up” to standardize strand polarity, ultra-
high throughput sequencing was performed by Illumina sequencing-by-
synthesis reaction.  The sequencing reaction consists of stepwise cycles that 
proceed iteratively; total cycle number dictates read length.  For the samples 
described here, 36 cycles were used to generate reads 36 nt in length.  Polymerase 
extends the 3' end of primer (annealed in the final amplification step) through 
incorporation of fluorescently labeled (by base), reversibly terminating 
nucleotides.  After the incorporation of one chain-terminating nucleotide, the 
entire flowcell is imaged in small “tiles,” 120 tiles per lane.  Four images are 
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captured per tile, one for each nucleotide laser/filter combination. A cleavage 
step removes the fluorophore and reverses chain termination.  After a wash step, 
the cycle is repeated until the desired read length has been reached. 
Raw image data were processed using the standard Illumina software 
pipeline (SCS2.4).  Real-time analysis and basecalling generated files containing 
data on each sequencing read (*qseq.txt), intensities (*.cif) and noise profiles 
(*.cnf). Due to the nature of the sequencing methodology, certain corrective 
measures are implemented to account for spectral crosstalk from the 
fluorophores and the fact that not all strands in each cluster are extended in 
perfect synchrony; some will not be extended and others will be extended by two 
bases at certain cycles, leading to what is termed “phasing.”  Spectral crosstalk 
and phasing were corrected using the Bustard (GA Pipeline 1.4.0) program and 
the phiX174 control lane as recommended by Illumina.  The resulting *qseq.txt 
files contain read IDs, sequence, and quality scores for each flowcell tile.  
Standard FASTQ files were generated using the Gerald (GA Pipeline 1.4.0) 
program. 
2.2.4.  Mapping RNA-Seq reads to the reference genome 
 Prior to mapping, RNA-Seq reads were examined for overall quality and 
base content.   Present analysis and prior evidence indicated that priming reverse 
transcription with random hexamer primers leads to an overrepresentation of G 
and C residues in the initial sequencing cycles.  To eliminate this potential source 
of error, prior to mapping, each short read was “trimmed” – the 5′ first two bases 
(and associated quality information) were digitally removed from the FASTQ 
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data files with the FASTQ/A Trimmer tool, part of the FASTX Toolkit software 
package (available at http://hannonlab.cshl.edu/fastx_toolkit/index.html). 
 The rationale and strategy for RNA-Seq read mapping is detailed above.  
Based on the mapping criteria described, reads were mapped to the C57/BL6 
reference mouse genome (NCBI37/mm9) using the Tuxedo Tools software 
packages, Bowtie (short read alignment) (Langmead et al., 2009) and TopHat 
(spliced read mapping for RNA-Seq) (Trapnell et al., 2009).  A GFF file of RefSeq 
gene models was supplied to supplement exon-exon junction mapping.  The 
command line parameters for mapping and alignment were as follows: 
$ tophat –n 2 -g 1 --segment-length 34 -a 12 -m 1  -p 8 –G <RefSeq.gff3> 
<mm9_genome> <Read_Files.fastq> 
 
-n 2 allow for up to 2 mismatches to reference in seed region (first 28nt); 
quality conscious 
-g 1 suppress all alignments for reads that map to >1 location in 
reference 
--segment-length 34 read length is 34 nt for alignment 
-a 12 for exon-exon junction reads, require at least 12 bases (“anchor”) on 
either side of junction 
-m 1 for exon-exon junction reads, allow for up to 1 mismatch in anchor 
segment 
-p 8 use 8 processor cores for computations 
-G supplement splice junction mapping with supplied gene model 
annotation file <RefSeq.gff3> 
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The resulting SAM output files were used in downstream mismatch analysis and 
“wiggle” plot output files were visualized with the UCSC genome browser to 
evaluate read coverage of expressed transcripts. 
RNA-Seq read analysis, trimming, mapping and alignment were 
performed on virtual server instances provided by the Amazon Elastic Compute 
Cloud (EC2) (http://aws.amazon.com/ec2/) and running Ubuntu Linux version 8.0 
or above. 
2.2.5.  Transcriptome sequence analysis 
 According to the analysis strategy detailed above, single nucleotide 
read:reference mismatches were identified with the SAMTools software package 
(Li et al., 2009a).  The standard SAMTools workflow was used to generate a 
pileup output that contained all mapped RNA-Seq reads and their quality scores 
on a reference base-by-base scale and a corresponding consensus base call at each 
position.  This information was used to identify single nucleotide variants in the 
wild-type dataset with a quality-conscious algorithm (Li et al., 2008). 
The index of read:reference variant sites was filtered on several criteria to 
restrict analysis to those mismatches related to APOBEC1 editing.  First, as many 
mismatch sites are the result of off-target mapping to intergenic and intronic 
sites, only those sites that mapped to RefSeq exons (UCSC Table Browser, NCBI 
37/mm9) were retained.  Next, to identify sites consistent with APOBEC1 
cytidine deaminase activity, only sites at which the reference base was a C and 
the read consensus call included T were selected for additional consideration.  
Mismatch sites annotated as SNPs (dbSNP build 128, available at 
ftp.ncbi.nih.gov/snp) were also discarded.  Finally, the remaining sites were 
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compared to read consensus base calls in the apobec1-/- dataset.  Only those sites at 
which wild-type read consensus contained C:T mismatches and apobec1-/- read 
consensus contained a high-confidence C:C match were deemed potential editing 
sites.  This list was further reduced by removing those sites with insufficient read 
depth (<5 reads for wild-type, <3 reads for apobec1-/-) and/or insufficient 
confidence scores (Phred-scaled mismatch probability < 45 for wild-type, Phred-
scaled consensus probability < 30 for apobec1-/-).   
 Unless otherwise described, all analysis filters and database queries were 
performed with standard shell scripts or the Galaxy genomics web portal 
(http://g2.bx.psu.edu) (Taylor et al., 2007).  
2.2.6.  APOBEC1 editing site validation 
Genomic DNA and RNA were prepared from wild-type and apobec1-/- 
small intestine by standard methods.  cDNA was prepared from total RNA by 
Superscript III reverse transcriptase (Inivitrogen) and random hexamer priming.  
Sequences containing potential APOBEC1 editing sites were PCR amplified 
using TurboPfu high-fidelity polymerase (Stratagene).  Primer extension 
sequencing was performed by GENEWIZ, Inc. (South Plainfield, NJ) using 
Applied Biosystems BigDye version 3.1.  The reactions were then run on Applied 
Biosystem's 3730xl DNA Analyzer. 
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2.3.  Results 
 
2.3.1.  RNA-Seq screen for APOBEC1 mRNA editing sites - small intestine 
 To test the efficacy and feasibility of the proposed experimental approach 
for identifying deaminase-specific mRNA editing sites, the comparative RNA-
Seq screen was applied to the small intestine transcriptome.  Jejunal segments 
were isolated from C57/BL6 wild-type and congenic apobec1-/- mice.  RNA-Seq 
libraries were prepared from polyA+ mRNA and sequenced by ultra-high 
throughput methods.  As a pilot study, a relatively low number of reads were 
acquired: 13,698,876 reads for wild-type, 15,040,776 reads for apobec1-/-.  Reads 
were mapped to the mouse reference genome (mm9, NCBI 37.1), allowing for up 
to two mismatches per sequence.  Only reads with sufficient quality scores that 
mapped to unique sites in the genome were used for analysis (8,297,959 reads for 
wild-type, 8,365,157 reads for apobec1-/-).  A qualitative analysis of read 
distribution indicated that, while not comprehensive, read coverage of 
transcripts at moderate to high expression levels was extensive and somewhat 
evenly distributed (Figure 2.4). Gaps in otherwise well-covered transcripts were 
usually a result of repetitive or low-complexity local sequence content. 
 The strategy for detecting potential RNA editing events described above 
was applied to the mapped read datasets.  Sites within RefSeq exons at which the 
reference genome contained a C and wild-type reads contained Ts (or reference 
G and RNA-Seq read As for (-)-strand transcripts, in genomic context) were 
compared to corresponding apobec1-/- reads.  Sites at which the apobec1-/- read 
consensus matched the reference sequence were considered for additional 
















chr7:149561821 - 149573775 (-)
Figure 2.4. RNA-Seq read coverage of a transcript expressed at moderate 
levels in small intestine.  The Ctsd gene encoding cathepsin D serves as a 
representative example for transcript read coverage.  As RNA-Seq libraries are 
prepared from polyA+ mRNA, reads map predominantly to exons (thick blue 




mismatch/consensus probability scores, 35 remaining sites were designated 
candidate APOBEC1 editing targets (Table 2.1).  When sites were ranked by 
mismatch probability score and read depth, the top hit was the well-
characterized editing site in apoB mRNA. This result confirmed that the 
sequencing methodology and analysis pipeline can successfully detect single 
nucleotide editing events on a transcriptome scale. 
 Though the detection of editing in apoB mRNA was anticipated, the 
significance of the other 34 candidate editing sites indentified in the screen was 
somewhat unclear.  While the various analysis filters were designed to minimize 
mismatches unrelated to specific RNA editing activity, some false positive hits 
were expected.  Sample-specific false positives could be caused by sequencing 
errors, PCR amplification of polymerase errors, unannotated SNPs or read 
mapping artifacts.  Alternatively, the candidate sites could represent genuine, 
previously undescribed APOBEC1 RNA editing targets.   
These possibilities were explored by additional examination of RNA-Seq 
data and validation experiments.  For each candidate site, individual read 
alignments were assessed for base content and potential artifacts.  As expected 
based on filter design, mismatches were consistent with cytidine deaminase 
activity; if distinct from reference, variant bases were almost always T (or A for (-
)-strand transcripts).  There was no evidence of non-specifically mixed nucleotide 
mismatches.  Furthermore, reads covering candidate sites were often staggered, 
with a range of distinct start and end coordinates.  This diminishes the likelihood 
that mismatches were caused by PCR amplification of revere transcriptase or 
polymerase errors during library preparation, as they would be expected to 
appear as identical reads.  However, unlike the apoB target site, at which greater 
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Table 2.1.  Candidate APOBEC1 editing sites (small intestine)
    wild-type  apobec1-/- 























chr12:8014860(+) Apob C  T 255 255 266 0.94  C 255 0 200 0.00 
chrX:109671648(+) 2010106E10Rik C  Y 228 228 181 0.43  C 254 0 99 0.00 
chr8:46391931(-) Cyp4v3 G  R 228 228 105 0.32  G 129 0 34 0.00 
chr2:121978638(+) B2m C  Y 228 228 323 0.26  C 255 0 173 0.00 
chr16:84955113(-) App G  R 228 228 82 0.28  G 250 0 74 0.00 
chrX:136207009(+) Rnf128 C  Y 216 216 167 0.22  C 219 0 87 0.00 
chr3:129616676(+) Casp6 C  Y 193 193 56 0.25  C 167 0 59 0.00 
chr3:73442586(-) Bche G  R 191 191 33 0.33  G 57 0 10 0.00 
chr18:24445094(+) Galnt1 C  Y 107 107 12 0.42  C 60 0 11 0.00 
chr15:99239051(+) Tmbim6 C  Y 107 107 90 0.18  C 255 0 104 0.00 
chr3:73442584(-) Bche G  R 106 106 34 0.24  G 36 0 13 0.00 
chr12:38308269(+) Tmem195 C  Y 104 104 13 0.38  C 48 0 7 0.00 
chr5:87984364(-) Sult1d1 G  R 102 102 15 0.33  G 48 0 7 0.00 
chr10:57235791(-) Serinc1 G  R 96 96 19 0.32  G 57 0 10 0.00 
chr1:192830761(-) Mfsd7b G  R 35 95 14 0.79  G 69 0 14 0.00 
chr17:44416335(+) Clic5 C  Y 86 86 29 0.21  C 93 0 22 0.00 
chr12:88650627(-) Sptlc2 G  R 83 83 13 0.31  G 60 0 11 0.00 
chrX:106355759(+) Sh3bgrl C  Y 79 79 13 0.31  C 48 0 7 0.00 
chr13:96397211(-) Iqgap2 G  R 74 74 9 0.44  G 51 0 8 0.00 
chr13:96397404(-) Iqgap2 G  R 67 67 12 0.33  G 57 0 10 0.00 
chr17:43611473(-) Mep1a G  R 62 62 17 0.24  G 42 0 5 0.00 
chr18:6789843(+) Rab18 C  Y 61 61 9 0.33  C 42 0 5 0.00 
chr3:73443602(-) Bche G  R 60 60 14 0.29  G 42 0 5 0.00 
chr1:90115552(+) Ugt1a5 C  Y 60 60 22 0.23  C 75 0 16 0.00 
chr14:79981748(+) Elf1 C  Y 56 56 8 0.38  C 69 0 14 0.00 
chr14:73762178(-) Itm2b G  R 56 56 7 0.43  G 51 0 8 0.00 
chrX:106356686(+) Sh3bgrl C  Y 55 55 33 0.21  C 105 0 26 0.00 
chrX:109671857(+) 2010106E10Rik C  Y 54 54 29 0.21  C 66 0 13 0.00 
chr7:96290044(-) Tmem135 G  R 53 53 8 0.38  G 42 0 5 0.00 
chr2:109739674(+) Lin7c C  Y 53 53 16 0.25  C 99 0 24 0.00 
chr1:4835552(+) Lypla1 C  Y 53 53 31 0.16  C 65 0 26 0.00 
chr5:65805030(-) Ugdh G  R 48 48 45 0.13  G 123 0 44 0.00 
chr12:38308281(+) Tmem195 C  Y 48 48 45 0.13  C 87 0 20 0.00 
chr11:20125336(+) Rab1 C  Y 46 46 34 0.18  C 120 0 31 0.00 
chr11:109313859(-) Slc16a6 G  R 46 46 14 0.21  G 54 0 9 0.00 
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than 90% of the wild-type RNA-Seq reads contained a T instead of the reference 
C, wild-type samples at the other candidate sites contained smaller proportions 
of mismatch-containing reads. 
2.3.2.  Validation of candidate editing sites in small intestine 
In order to determine if the candidates identified in the RNA-Seq screen 
could represent actual targets of APOBEC1 editing, several sites were selected 
for experimental validation.  Standard dideoxynucleotide Sanger sequencing was 
used to examine the sites in genomic DNA and cDNA derived from murine 
intestine. All validation samples were independently prepared from different 
mice than those used for RNA-Seq libraries.  Evidence of APOBEC1-dependent 
C-to-U(T) mRNA editing was apparent in 15 of 16 sites examined.  
Representative examples of sequencing chromatograms appear in Figure 2.5.  
The C/T chromatogram peaks from wild-type cDNA were of varied intensities, 
with C as the dominant peak in most sequences.  This observation is consistent 
with the low fraction of mismatch-containing wild-type RNA-Seq reads.  
Nonetheless, these experiments confirm that APOBEC1 edits additional mRNAs 
other than the apoB transcript and that these sites can be identified by the 
comparative RNA-Seq screening method described here. 
The recognition of additional targets for APOBEC1, an enzyme long 
thought to be monospecific for apoB mRNA, raises many additional questions 
regarding the enzyme’s specificity, efficiency and physiological functions.  
Though this pilot study demonstrated proof of principle for both the RNA-Seq 
screening approach and APOBEC1-specific editing beyond apoB, it had several 
























Figure 2.5. Validation of candidate APOBEC1 editing sites in whole 
intestine.  Representative examples of conventional Sanger sequencing for 
whole intestine genomic DNA (gDNA) and mRNA (reverse-transcribed to 
cDNA) are shown. C-to-U(T) editing is apparent only in wild-type cDNA.  (A) 






relatively high levels, the number of RNA-Seq reads generated by ultra-high 
throughput sequencing was inadequate for extensive single-nucleotide coverage 
of the transcriptome.  Next, a considerable proportion of RNA-Seq reads were 
likely generated from transcriptomes irrelevant for APOBEC1 editing.  As whole 
tissue was used to prepare RNA-Seq libraries, mRNA was extracted from the 
diverse cellular components of the small intestine, including absorptive 
enterocytes, goblet cells, Paneth cells, enteroendocrine cells, smooth muscle 
myocytes, leukocytes of the lamina propria, and others.  Within the intestine, 
APOBEC1 is only expressed by the absorptive enterocytes of the luminal 
epithelium (Funahashi et al., 1995).  Therefore, for a given transcript expressed in 
enterocytes and other intestinal cell types, RNA-Seq reads with mismatches 
attributable to enterocyte APOBEC1 editing would be “diluted” by non-
enterocyte reads.  Though not an issue for the enterocyte-specific apoB mRNA 
(Funahashi et al., 1995), this mixed transcriptome problem could reduce the 
sensitivity of the screen and could be partially responsible for the apparently low 
efficiency or incomplete editing observed at newly identified sites.  Therefore, in 
order to more thoroughly investigate APOBEC1 mRNA editing, the comparative 
RNA-Seq screening approach was applied to small intestinal enterocytes, as 
described in Chapter 3. 
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CHAPTER 3: IDENTIFICATION OF APOBEC1 mRNA EDITING TARGETS 
IN SMALL INTESTINAL ENTEROCYTES 
 Following the discovery and characterization of APOBEC1 as the catalytic 
activity responsible for apoB mRNA editing, attempts have been made to 
identify additional editing targets (Smith et al., 2005).  With the exception of NF1 
transcript editing in a subset of peripheral nerve sheath tumors (Mukhopadhyay 
et al., 2002; Skuse et al., 1996), no other physiological mRNA targets have been 
identified.  During the development and validation of a comparative RNA-Seq 
screening method to detect editing targets (Chapter 2), APOBEC1-specific editing 
was observed and validated in apoB mRNA as well as several additional 
transcripts in the small intestine.  Although this pilot study was somewhat 
limited in scale, it prompted a more comprehensive examination of APOBEC1 
editing in which the RNA-Seq screening method was applied to small intestinal 
enterocytes.  With additional read depth and superior tissue preparations, 
numerous APOBEC1 mRNA editing targets were identified in the screen and 
subsequently validated by standard techniques.  Unlike the well-characterized 
site in the apoB coding sequence, these newly recognized editing sites are all 
located in the 3’ UTRs of diverse transcripts.  These sites share several 
characteristic sequence features, including a downstream (3’) motif similar to the 
mooring sequence in apoB mRNA.  Bioinformatics analysis based on these 
features successfully predicted additional APOBEC1 targets that were not 
represented in the RNA-Seq screen.  Many APOBEC1 editing sites are located 
within transcript regions significantly conserved in mammalian evolution, 
implying possible functional importance.  These findings dramatically expand 
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the list of APOBEC1 mRNA editing targets, thereby suggesting additional 
functions for this enzyme beyond its previously characterized role. 
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3.1.  Experimental Procedures 
 
3.1.1.  Mice 
All C57/BL6 wild-type and congenic apobec1-/- mice were used at 6-8 weeks of 
age.  Apobec1-/- mice (Hirano et al., 1996) were generously provided by N. 
Davidson (Washington University School of Medicine, St Louis, MO). 
3.1.2.  Isolation of small intestinal enterocytes 
 Mouse small intestines were removed and washed in Hanks Buffered 
Saline Solution (HBSS) with Ca2+ and Mg2+.  Jejunum segments were dissected, 
everted and cut into ~5 cm pieces.  Enterocytes were isolated with a protocol 
adapted from (Xie et al., 2003): Jejunum segments were washed 5 times in HBSS 
(supplemented with Ca2+ and Mg2+) containing 1% fetal bovine serum (FBS) and 
then washed once in HBSS (without Ca2+ and Mg2+) containing 2% glucose and 
2% bovine serum albumin (BSA).  Jejunum segments were transferred to 
enterocyte isolation buffer (HBSS without Ca2+ and Mg2+, 1.5 mM EDTA, 0.5 mM 
DTT) and incubated at 37°C with agitation (120 rpm on rotational shaker) for 30 
minutes.  Enterocyte cell suspensions were collected, passed through a 70 µm cell 
strainer, washed and resuspended in TRI Reagent (Ambion) for RNA 
preparation or processed for immunolabeling and flow cytometry. 
3.1.3.  Immunolabeling, fluorescence microscopy and flow cytometry 
For immunolabeling, enterocyte preparations were pre-incubated with Fc 
Block (BD Biosciences) and then labeled with PE-Cy7-conjugated antibodies 
against pan-leukocyte marker CD45 (BD Biosciences).  Cells were washed, fixed 
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and permeabilized with Cytofix/Cytoperm solutions (BD Biosciences).  After 
blocking with 5% goat serum (Invitrogen), enterocyte preps were labeled with 
polyclonal antibodies against villin-1 (Cell Signaling Technology), an enterocyte-
specific marker.  Secondary labeling was achieved with AlexaFluor 594-
conjugated goat anti-rabbit F(ab’)2 fragment. 
For flow cytometry, cells were resuspended in acquisition buffer (PBS, 5% 
FBS) and acquired on an LSR II cell analyzer (BD Biosciences). 
For fluorescence microscopy, cells were transferred to slides by Cytospin 
(Thermo Scientific) centrifugation, labeled with DAPI, and mounted in 
VECTASHIELD medium (Vector Labs).  Images were acquired on an Axioplan 2 
fluorescence microscope (Zeiss) and processed with Metamorph software 
(Molecular Devices). 
3.1.4.  Preparation of RNA-Seq libraries 
 Enterocyte total RNA was prepared by TRI Reagent (Ambion) extraction 
and treated with TURBO DNase (Ambion).  RNA-Seq libraries were prepared 
and sequenced as described in Chapter 2. 
3.1.5.  Mapping RNA-Seq reads and transcriptome sequence analysis 
 
 All read mapping and mismatch analyses were performed as described in 
Chapter 2. 
3.1.6.  RNA-Seq transcriptome profiling 
 Transcriptome expression profiling was performed with the Cufflinks 
software package (available at: http://cufflinks.cbcb.umd.edu/).  Wild-type and 
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apobec1-/- RNA-Seq alignments (generated by TopHat) were mapped to RefSeq 
gene models and relative transcript abundances were calculated based on read 
distribution. 
3.1.7.  RNA-Seq read coverage analysis 
 RNA-Seq read coverage at single-nucleotide resolution was calculated by 
merging read pileup statistics (SAMtools) with transcript models of expressed 
genes.  Expressed genes were defined as RPKM ≥ 1.0 by RNA-Seq expression 
analysis.  Expressed genes were subdivided into four groups by quartile 
(RPKM): Very low, low, moderate, and high expression levels.  Genomic 
coordinates for expressed gene exons were derived from RefSeq transcript 
annotations.  These coordinates were merged with SAMtools pileup output to 
determine the number of reads covering each nucleotide position in expressed 
transcripts. 
3.1.8.  APOBEC1 editing site validation 
 Genomic DNA and RNA were prepared from wild-type and apobec1-/- 
small intestine enterocytes by standard methods.  cDNA was prepared from total 
RNA by Superscript III reverse transcriptase (Inivitrogen) and random hexamer 
priming and/or 3’RACE oligo(dT) priming (Invitrogen).  Sequences containing 
potential APOBEC1 editing sites were PCR amplified using TurboPfu high-
fidelity polymerase (Stratagene).  Primer sequences appear in Supplemental 
Table S3.  Primer extension sequencing was performed by GENEWIZ, Inc (South 
Plainfield, NJ) using Applied Biosystems BigDye version 3.1.  The reactions were 
then run on Applied Biosystem's 3730xl DNA Analyzer. 
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For subclone sequencing, PCR products were cloned into pSC-B vectors 
(Stratagene) and transformation colonies were selected by blue/white screening 
on X-gal LB agar plates.  Individual colonies were picked and sequenced as 
above. 
3.1.9.  APOBEC1 editing site features: AU content analysis 
Bioinformatic analyses of transcript AU content were performed in 
collaboration with Michael Mwangi (Rockefeller University, New York, NY). 
For mRNA feature analysis, several bioinformatic issues regarding 
sequence annotations were addressed.  As the RNA-Seq screen operates on 
genomic coordinates, analysis considerations were made to adjust for editing at 
the transcript level.  Due to alternative splicing, a gene can generate multiple 
mRNA isoforms, and when the transcribed but untranslated 3' sequence of a 
gene contains multiple exons, multiple 3' UTR isoforms may exist. As a result, a 
single APOBEC1 edit site can appear in different mRNA transcript and 3' UTR 
annotations.  Therefore, computations were performed at the DNA level over 
specific genomic intervals, herein referred to as GIs. These intervals are the exon 
segments that code for portions of 3' UTR isoforms as defined in the RefSeq 
database. It is important to emphasize that the term “GI” is used very specifically 
here and does not simply refer to exons. While there are a total of 26,558 GIs 
annotated in the mouse genome, there are many more exons.  
The issue of overlapping GIs was also considered.  It was determined that 
this issue was a non-factor in computations and therefore was ignored.  None of 
the GIs that contain an APOBEC1 edit site overlap with another GI, and <5% of 
the GIs genome-wide overlap with another GI. 
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Furthermore, though the computations were performed at the DNA level, 
the U designation (in place of T) was used because the results relate to an editing 
event at the transcript level. 
 In assessing AU enrichment of the GIs that contain editing sites, the AU 
content of a set of sequences was defined simply as the number of A- and U-
nucleotides divided by the number of total nucleotides in all sequences of the set.  
For comparison, random sets of GIs were constructed as follows: 
a. For each edit-site-containing GI, a GI was randomly selected from a 
pool of GIs of comparable length (±20%) according to a uniform 
distribution over the pool. If the length of the edit-site-containing GI is 
l, then the length of the new GI was ensured to be in the interval [0.8l, 
1.2l]. Since the GIs are of varying sizes, it was important to control for 
length. For example, very long GIs may have sparsely distributed 
functional elements and so may have long stretches that are not subject 
to purifying selection. Depending on the edit-site-containing GI, there 
were a minimum of 262 GIs of comparable length to randomly choose 
from and a maximum of 1037, with a median of 949. Therefore, there 
was ample choice, so the random sets were diverse and rarely 
contained the same elements. 
b. A random set was allowed to include edit-site-containing GIs. 
c. A random set was not allowed to contain multiple instances of the 
same GI. If a GI was randomly selected that was selected before, the 
repeat instance was discarded, and the random selection was redone 
until a unique GI was obtained. 
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The AU content of the edit-site containing GIs was compared to the AU content 
of each of 100,000 comparable random sets of GIs to evaluate significant 
enrichment. 
In assessing the AU-richness of 101 nt windows centered on the edit sites, 
the AU content of a set of sequences is defined as above.  For cases in which 
multiple edit sites occurred within the same 101 nt window, sites were 
condensed to a single coordinate.  For statistical comparisons, random sets of 101 
nt windows were constructed as follows: 
a. For each edit-site-containing window, a window of the same length 
was randomly selected from within the same GI according to a 
uniform distribution over the GI. The GIs had lengths ranging from 
299-4629 nt, with a median of 1380 nt.  Therefore, there was ample 
choice, so the random sets were diverse and rarely contained the same 
elements. 
b. A random set was allowed to include windows that overlapped with 
edit sites. 
c. A random set was not allowed to contain windows that overlapped 
with each other – overlapping windows result in double counting and 
can arise in the case of edit sites in the same GI. If a window was 
randomly selected that overlapped with a previously selected window, 
the instance was discarded, and the random selection was redone until 
a non-overlapping window was obtained. 
The AU content was computed for the edit site set and compared to the AU 




3.1.10.  APOBEC1 editing site features: Adjacent nucleotide analysis 
Following sequence alignment by editing sites, the bionomial test was 
used to assess an apparent preference for A and U nucleotides at positions 
immediately flanking the target cytidine.  For N editing sites, the total number of 
nucleotides in a given sequence alignment column is always equal to N.  Let k be 
the number of A- and U-nucleotides in the column.  P-values for each column 
were computed from the binomial distribution: 
 
The background AU frequency fAU was calculated as described above.  The 
reported P-values represent the probability of observing ≥k A- or U-nucleotides 
in a given column under the null hypothesis that A- or U-nucleotides occur with 
the background frequency fAU. 
3.1.11.  APOBEC1 editing site features: Sequence motif analysis 
Sequence motif analysis was performed with the Multiple Em for Motif 
Elicitation (MEME) algorithm (http://meme.nbcr.net/meme4_3_0/cgi-bin/meme.cgi) 
(Bailey and Elkan, 1994) on a set 101 nt sequences centered on the editing sites.  
Statistical significance was approximated by comparing the log likelihood ratio 
and E-value of the best reported hit to those of the top hit returned by an 
identical analysis of randomly-shuffled input sequence. 
All logo and frequency plots were generated with WebLogo  
(http://weblogo.berkeley.edu/) (Crooks et al., 2004). 
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3.1.12.  APOBEC1 sequence pattern analysis 
 SequenceSearcher software (http://athena.bioc.uvic.ca/tools/SequenceSearcher) 
(Marass and Upton, 2009) was used to perform regular expression searches for 
the APOBEC1 consensus sequence pattern within a compiled collection of all 
RefSeq exon sequences.  The list of predicted sites was filtered on gene 
expression level in wild-type small intestinal enterocytes.  When sufficient 
coverage was available (≥ 3 reads), wild-type RNA-Seq reads mapped to each 
site were examined for evidence of editing (C:T mismatches above a background 
frequency of 0.075). 
3.1.13.  Assessment of phylogenetic conservation 
Phylogenetic analyses of conservation and C-T mutation bias were 
performed in collaboration with Michael Mwangi (Rockefeller University, New 
York, NY). 
PhastCons scores were used to evaluate phylogenetic conservation.  In the 
phastCons analysis, a score is assigned to each nucleotide of the mouse genome 
in reference to a multialignment of 19 other genomes (placental mammals). The 
score is in the interval [0, 1] and reflects the degree of conservation across the 
included species genomes (Siepel et al., 2005).  As the mouse serves as the 
“reference” species in this analysis, scores are not assigned to insertions or 
deletions in the mouse genome relative to the multialignment. 
For a set of 101 nt windows in mouse GIs, the mean phastCons score was 
computed as follows. First, the sum of the phastCons scores over all nucleotides 
in all of the windows was computed.  This cumulative score was then divided by 
the total number of nucleotides within the set of windows.  Random sets of 
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windows comparable to those containing APOBEC1 editing sites were 
constructed as described above.  The mean phastCons score was computed for 
each of 10,000 random sets of windows and compared to the mean phastCons 
score of the editing site set, with the corresponding P-value indicating the 
significance of phylogenetic conservation. 
3.1.14.  Assessing C-T bias at APOBEC1 sites in genomic multi-alignments 
An observed bias of C and T nucleotides in multispecies genomic 
alignments to mouse edit sites was examined quantitatively by statistical 
comparison.  For a site X in the placental mammalian genomic alignment, let 
D(X) equal the number of times the C (G) in mouse differs from a base in another 
mammal, not including indels.  Let d(X) equal the number of times the C (G) in 
mouse is replaced by a T (A) in another mammal. The following quantity was 
used as a measure of the C-to-T (G-to-A) bias for validated APOBEC1 editing 
sites: 
. 
Essentially, B is the fraction of changes that involve C-to-T (G-to-A) differences 
between mouse and the other mammals. The larger B is, the higher the bias. The 
value of B for the APOBEC1 editing sites was compared to values for random 
sites, and the results were used to compute a P-value. 
 Though APOBEC1 editing at the mRNA level always occurs at cytidine 
residues, editing sites within (-)-strand transcripts are represented as G in 
genomic context.  For analyzing nucleotide bias within genomic multi-
alignments, it is important to take strand information into account, as strand 
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asymmetries may exist with regard to phylogenetic substitutions.  For example, 
it has been reported that C-to-T substitutions do not occur at equal rates on both 
strands, which is equivalent to the statement that C-to-T and G-to-A substitutions 
occur at different rates on the (+) strand (Green et al., 2003).  Therefore, only (+) 
strand bases in the mouse genome were considered in the multi-alignment 
analysis presented here.    
 An example of a random set of multi-species alignment appears in Figure 
3.1B.  The random alignment sites used to assess the significance of B were 
subject to several important constraints. For each edit site-containing row X, a set 
R(X) of rows was considered.  For X, R(X) would serve as the pool from which 
rows would be randomly drawn. The set R(X) contained any row Y in the multi-
species alignment that satisfied the following conditions: 
a. Y must be within a 3’ UTR GI.  
b. The base in mouse in Y must be identical to the base in mouse in X 
(e.g. both rows 1 in Figures 3.1 have a G). 
c. Y must have the same number of indels as X (e.g. both rows 1 have 7 
indels).  
d. D(Y) = D(X), where the quantity D(X) was defined above (e.g. both 
rows 1 have a value of 10).   
e. The phastCons score for Y must agree with the phastCons score for X 
to within ±0.2. This constraint is almost redundant. A row Y that 
satisfies criterions (c)-(d) often satisfies this criterion. 
Hence, the pool R(X) consisted of rows that are very similar to X – they have the 
same base composition in mouse and nearly identical degrees of conservation. 
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Depending on X, R(X) contained a minimum of 530 elements and a maximum of 
44,023, with a median of 13,449.5. Therefore, there was ample choice, so the 
random sets were diverse and rarely contained the same elements. 
3.1.15  Estimation of miRNA target sites 
In order to estimate if APOBEC1 editing affects miRNA targeting, two sets 
of sequences were assembled: one set in which 13 nt sequences were centered on 
the edited cytidines (6 nt upstream, 6 nt downstream) and one set in which 13 nt 
sequences were centered on the editing sites as uridine (6 nt upstream, 6 nt 
downstream).  These sequences were queried against known mature miRNAs 




































































chr1:152208563(-) G G - - A A A - A A C - G A - A A - A -
chr1:192830761(-) G - T - T T T T T - T - - T T C T T T T
chr10:7487994(-) G G - G G G G G G - - G G G G G T G G G
chr10:57235791(-) G A A A A A A A A A A - - T - G - - A -
chr10:69486962(+) C C C C C C C C C C C C - C - C C C C C
chr12:85772761(-) G G A G G G G G G - G G G G G G G - G T
chr13:96397211(-) G - - - G G G G G G G G G G - G G G G G
chr13:96397289(-) G - - - A A A A A G A - A A - G G G G G
chr14:73595382(-) G G G G G G G G G G G G G G - G G A G G
chr15:99239051(+) C C C C C C C C C C C C C C C C C C C C
chr16:43981376(-) G G G G G G G G G - G - G G C G - G - A
chr16:77116537(+) C C C - C C C C C C T C - C - C C C C C
chr16:84954758(-) G G G G G G G G G G G G G G G G G G G G
chr16:84955113(-) G G G G G G G G G G G G G G - G G - G G
chr17:44416335(+) C C A C C C C C C C C - C C C T C C C -
chr2:73654730(-) G G G C G G G G G G - G G G - G G - G G
chr2:121978638(+) C C - - T T T T - T T - - - - - T - - -
chr2:143811725(-) G G A A A A A A A A G - - - - - - - - -
chr3:73442586(-) G G - - A - - A - - - - - - - A - - A -
chr3:119135667(+) C C T T C C C C C C C C C C - C - - C C
chr3:119135669(+) C T T T T T T T T T T T C T - T - - T T
chr3:129616676(+) C C - T C C C C C T - - - C - C C C C C
chr3:144259976(+) C C T - T T T T T T T G T T T T T T T T
chr4:57203753(-) G G G T G G G G G - G - - - - G G - G G
chr4:94304303(-) G A - A A A A A A - A - - G - A - A - A
chr5:87984364(-) G A - A A A A A A - A - - - - G - A - -
chr8:46391931(-) G G - G G G - G G G - G G G G G G - G G
chr9:79617629(-) G G T G - - - - - G G A G G - G G G G G
chrX:50374459(+) C C C C C C C C C C - C A G - C C T C C
chrX:106355759(+) C C - T C - C C C C C - - A A A A - A -
chrX:109671648(+) C C - C C C C C C - - - - T - C - - C -

































































chr1:152 08563(-) G G - - A A A - A A C - G A - A A - A -
chr1:192830761(-) G - T - T T T T T - T - - T T C T T T T
chr10:74879 4(-) G G - G G G G G G - - G G G G G T G G G
chr10:57235791(-) G A A A A A A A A A A - - T - G - - A -
chr10:69486962(+) C C C C C C C C C C C C - C - C C C C C
chr12:857 2761(-) G G A G G G G G G - G G G G G G G - G T
chr13:9639721 (-) G - - - G G G G G G G G G G - G G G G G
chr13:96397289(-) G - - - A A A A A G A - A A - G G G G G
chr14:73595382(-) G G G G G G G G G G G G G G - G G A G G
chr15:9 239051(+) C C C C C C C C C C C C C C C C C C C C
chr16:43981376(-) G G G G G G G G G - G - G G C G - G - A
chr16:7 1 6537(+) C C C - C C C C C C T C - C - C C C C C
chr16:84954758(-) G G G G G G G G G G G G G G G G G G G G
chr16:8495 1 3(-) G G G G G G G G G G G G G G - G G - G G
chr17:4 163 5(+) C C A C C C C C C C C - C C C T C C C -
chr2:73654730(-) G G G C G G G G G G - G G G - G G - G G
chr2:121978638(+) C C - - T T T T - T T - - - - - T - - -
chr2:14381 725(-) G G A A A A A A A A G - - - - - - - - -
chr3:734 2586(-) G G - - A - - A - - - - - - - A - - A -
chr3:1 91356 7(+) C C T T C C C C C C C C C C - C - - C C
chr3:1 91356 9(+) C T T T T T T T T T T T C T - T - - T T
chr3:129616 76(+) C C - T C C C C C T - - - C - C C C C C
chr3:14 259 76(+) C C T - T T T T T T T G T T T T T T T T
chr4:57203753(-) G G G T G G G G G - G - - - - G G - G G
chr4:94304303(-) G A - A A A A A A - A - - G - A - A - A
chr5:87984364(-) G A - A A A A A A - A - - - - G - A - -
chr8:46391931(-) G G - G G G - G G G - G G G G G G - G G
chr9:79617629(-) G G T G - - - - - G G A G G - G G G G G
chrX:50374 59(+) C C C C C C C C C C - C A G - C C T C C
chrX:10635 759(+) C C - T C - C C C C C - - A A A A - A -
chrX:109671648(+) C C - C C C C C C - - - - T - C - - C -

































































1 G G - - A A A A A A - - - C C G A - A -
2 G A - - A A A A A A A - - A A A - A A A
3 G G - G G G G G G - G G G G G G G G - A
4 G G - C A A A A A - - - A A A - A - A A
5 C C C C C C C C C C C C - C C C C - C C
6 G G G G G G G G G - G G G G A G - G G A
7 G G - - G G G G G - G - G G G G G G G G
8 G G G A A A A A A G G - - A A G G - - -
9 G G G G G G G - G G G G G G G G G T G G
10 C C C C C C C C C C C C C C C C C C C C
11 G G - - G G G G G - G G G C C G G G - G
12 C C C C C C C C C C C - A C C C C C - -
13 G G G G G G G G G G G G G G G G G G G G
14 G G G - G G G G G G G - G G G G G G G G
15 C C C C C C C C C T C C A C C C C - C -
16 G G - G G G G G G G G T - - G G G G G G
17 C C T - T T T G G - G - - - - - - - - -
18 G C - - T T T C T C C - - G - G - - - -
19 G G - - - T - T T - - - - T - - - - - -
20 C T C C C C C C C C C - C T - C C - C C
21 C T - T T T - T T - T T T C T T T T T T
22 C C - C C C C C C C - - G C C C T - C -
23 C T T T T T T T T T T T T C T T T T - T
24 G G G G - - - - - G G G G G G G A - G G
25 G T T T - - T - - G - - T T - T T A T T
26 G G - - A A A - A A - - - A - A A A - -
27 G G - G G G G G G - G - G G G G G G - G
28 G G - G G G G G G - G - - A A G G G - -
29 C - A C C C C C C C C - C T C C C C T C
30 C C - - T T T T T T C - C C C - C - C -
31 C C C - C C C C C - - - - - - - - C A C

































































chr1:152208563(-) G G - - A A A - A A C - G A - A A - A -
chr1:192830761(-) G - T - T T T T T - T - - T T C T T T T
chr10:7487994(-) G G - G G G G G G - - G G G G G T G G G
chr10:57235791(-) G A A A A A A A A A A - - T - G - - A -
chr10:69486962(+) C C C C C C C C C C C C - C - C C C C C
chr12:85772761(-) G G A G G G G G G - G G G G G G G - G T
chr13:96397211(-) G - - - G G G G G G G G G G - G G G G G
chr13:96397289(-) G - - - A A A A A G A - A A - G G G G G
chr14:73595382(-) G G G G G G G G G G G G G G - G G A G G
chr15:99239051(+) C C C C C C C C C C C C C C C C C C C C
chr16:43981376(-) G G G G G G G G G - G - G G C G - G - A
chr16:77116537(+) C C C - C C C C C C T C - C - C C C C C
chr16:84954758(-) G G G G G G G G G G G G G G G G G G G G
chr16:84955113(-) G G G G G G G G G G G G G G - G G - G G
chr17:44416335(+) C C A C C C C C C C C - C C C T C C C -
chr2:73654730(-) G G G C G G G G G G - G G G - G G - G G
chr2:121978638(+) C C - - T T T T - T T - - - - - T - - -
chr2:143811725(-) G G A A A A A A A A G - - - - - - - - -
chr3:73442586(-) G G - - A - - A - - - - - - - A - - A -
chr3:119135667(+) C C T T C C C C C C C C C C - C - - C C
chr3:119135669(+) C T T T T T T T T T T T C T - T - - T T
chr3:129616676(+) C C - T C C C C C T - - - C - C C C C C
chr3:144259976(+) C C T - T T T T T T T G T T T T T T T T
chr4:57203753(-) G G G T G G G G G - G - - - - G G - G G
chr4:94304303(-) G A - A A A A A A - A - - G - A - A - A
chr5:87984364(-) G A - A A A A A A - A - - - - G - A - -
chr8:46391931(-) G G - G G G - G G G - G G G G G G - G G
chr9:79617629(-) G G T G - - - - - G G A G G - G G G G G
chrX:50374459(+) C C C C C C C C C C - C A G - C C T C C
chrX:106355759(+) C C - T C - C C C C C - - A A A A - A -
chrX:109671648(+) C C - C C C C C C - - - - T - C - - C -
chrX:136207009(+) C C C C C C C C C C C C C C - C C C C T
Figure 3.1. Genome multi-alignments for assessment of C-T bias.  (A) Multi-
alignments for APOBEC1 editing sites, (+) strand context. (B) Example of multi-
alignments for random sites.
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3.2.  Results 
 
3.2.1.  RNA-Seq screen for APOBEC1 mRNA editing targets in enterocytes 
 In order to more thoroughly evaluate APOBEC1 mRNA editing, the 
comparative RNA-Seq screen was applied to small intestinal enterocytes.  Jejunal 
enterocytes were isolated from the small intestine of C57/BL6 wild-type and 
congenic apobec1-/- mice (Figure 3.2 and Figure 3.3).  RNA-Seq libraries were 
prepared from poly-A+ mRNA and deep sequenced, generating 76,766,760 (wild-
type) and 50,509,000 (apobec1-/-) 36 nt reads.  Reads were trimmed and aligned to 
the mouse reference genome (mm9, NCBI 37.1) using the mapping strategy 
described in Chapter 2 (up to 2 mismatches per sequence, quality conscious, 
keeping only uniquely mappable reads).  Satisfactory alignments were achieved 
for 42,770,803 and 28,877,750 reads for wild-type and apobec1-/-, respectively 
(Table 3.1).  Read coverage of transcripts at single base resolution was extensive, 
particularly for genes expressed at moderate to high levels (Figure 3.4). 
Following RNA-Seq read mapping, candidate APOBEC1 mRNA editing 
sites were identified using the analysis strategy described in Chapter 2.  Briefly, a 
modified SNP-calling algorithm was used to find those sites within RefGene 
exons at which the reference genome contained a C and wild-type reads 
contained Ts (or reference G and RNA-Seq read As for (-)-strand transcripts, in 
genomic context).  These sites were then compared to apobec1-/- reads. If the 
corresponding position in apobec1-/- reads also contained the mismatch, the site 
was discarded as a likely genomic polymorphism or non-APOBEC1 























Figure 3.2.  Small intestinal enterocytes for RNA-Seq library preparations 
(flow cytometry).  Enterocytes were isolated from wild-type and apobec1-/- 
mice, labeled with villin-1 and CD45 antibodies, and analyzed by flow 
cytometry.  Villin-1+ CD45- enterocytes were the predominant cell population, 
with small numbers of contaminating Villin-1- CD45+ leukocytes.  (A) wild-








Figure 3.3.  Small intestinal enterocytes for RNA-Seq library preparations 
(immunofluorescence).  Enterocytes were isolated from wild-type and 
apobec1-/- mice, labeled with villin-1 and CD45 antibodies, and analyzed by 
Cytospin fluorescence microscropy.  Villin-1 labeling illustrates a polarized 
organization consistent with intestinal epithelial structure.  At high 
magnification (100x), characteristic microvilli are visible.  (A) wild-type, and 
(B) apobec1-/-.    
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Figure 3.4.  Estimation of RNA-Seq transcript coverage. Genes expressed in 
small intestine enterocytes were divided into expression groups (very low, 
low, moderate, high) by quartile.  Plots represent the number of individual 
base positions of expressed transcripts covered by the indicated number of 
mapped RNA-Seq reads.  Dashed red line indicates the cutoff for inclusion in 
candidate editing site analyses.  Inset tables report the fraction of individual 
base positions covered by at least 1 RNA-Seq read and at least the candidate 
editing site analysis cutoff value of mapped RNA-Seq reads. (A) wild-type, 
and (B) apobec1-/-.!      
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Raw Reads Uniquely Mapped Reads
wild-type 76,766,760 42,770,803 (56%)




wild-type read:reference mismatches (unfiltered) 44,250
Retain sites mapped to RefSeq exons 1,716
Retain reference C / read T mismatches 194
Remove known SNPs 181
Retain APOBEC1-specific mismatches
   (no mismatch in apobec1-/- read set)
93
Remove low read depth / low confidence sites 43
Remove mapping artifacts 39
Validate by Sanger sequencing 33
Table 3.1. RNA-Seq read dataset statistics
Table 3.2. Candidate APOBEC1 editing site statistics by analysis filter
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the reference sequence, the site was considered for additional analysis .  After 
filtering out those sites with insufficient read coverage (<5 reads for wild-type, 
<3 for apobec1-/-) and/or mismatch probability scores (Table 3.2), 39 remaining 
sites were designated candidate APOBEC1 mRNA editing targets.  As in the 
whole intestine pilot study, when these sites were ranked by mismatch 
probability score, the top hit was the apoB mRNA editing target.  Once again, 
unbiased detection of this positive control site indicated a successful screen and 
supported further analysis of the additional candidate targets.  An example of 
RNA-Seq read alignments is presented in Figure 3.5. 
3.2.2.  Validation of candidate editing sites in enterocytes 
 To validate the potential editing events identified in the RNA-Seq screen, 
standard dideoxynucleotide Sanger sequencing was used to examine the sites in 
genomic DNA and RNA (cDNA) isolated from intestinal enterocytes.  All 
validation samples were independently prepared from different mice than those 
used for RNA-Seq libraries.  Sanger sequencing results for several sites are 
presented in Figure 3.6.  Clear evidence of C-to-U(T) RNA editing was observed 
at 33 of the 39 candidate sites.  Sequencing results for 6 sites did not indicate 
editing; these candidates were rejected as false positive events.  The remaining 
C/T chromatogram peaks in wild-type cDNA were of varied intensity, 
indicating differences in editing levels.  However, the T chromatogram peaks 
were considerably more prominent at many sites as compared to sequencing 
data for whole intestine tissue (Chapter 2 – Figure 2.5).  This suggests that edited 
transcripts in whole intestine preparations were “diluted” by unedited 
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Figure 3.5.  Identification of candidate APOBEC1 editing sites by comparative RNA-
Seq screen: Tmem30a. (A) Genome annotation for Tmem30a indicates two alternatively-
spliced transcript models.  RNA-Seq read (blue squares, wild-type; red squares, 
apobec1-/-) distribution suggests that the first (dark blue, upper) is the most abundant 
isoform in intestinal enterocytes. A potential APOBEC1 edit site was identified in the 3’ 
UTR.  (B) Detail of region containing candidate APOBEC1 edit site (yellow box, A). 
RNA-Seq reads provide overlapping coverage at single-nucleotide resolution.  
Mismatches to reference are highlighted yellow.  The edit site displays numerous T 
reads in the wild-type sample, but only C reads in the apobec1-/- sample. 
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significant additional editing was observed at a cytidine adjacent to the location 
identified by the screen.  To further validate APOBEC1-specific editing, several 
sites were selected for subcloning and additional Sanger sequencing (Figure 3.7 
and Figure 3.8).  C/T mismatches at candidate editing sites were observed only 
in subclones derived from wild-type cDNA; no deviations from reference 
sequence were present in wild-type genomic DNA, apobec1-/-genomic DNA or 
apobec1-/- cDNA.  Additionally, low level “hyperediting” of C residues in close 
proximity to the primary editing site was observed in a minority of subclones for 
several targets, including apoB.  This phenomenon has been previously 
described for apoB mRNA (Figure 3.9) and is of unknown functional significance 
(Sowden et al., 1996a; Sowden et al., 1998; Yamanaka et al., 1996). 
A list of validated APOBEC1 mRNA editing targets appears in Table 3.3.  
Unlike the edited coding sequence of apoB mRNA, all of the newly identified 
APOBEC1 sites are located in transcript 3’ UTRs.  RNA-Seq read data were used 
to estimate the editing level of each site ([# of T reads] / [# of C reads + # of T 
reads]).  ApoB mRNA displayed the most pronounced editing (0.92), with 
editing frequency of 3’ UTR sites ranging from 0.18 to 0.79 (Figure 3.10).  Editing 
frequencies calculated from RNA-Seq reads were very similar to those 
determined by cDNA amplification, subcloning, and Sanger sequencing. 
3.2.3.  Transcriptome profiling of wild-type and apobec1-/- enterocytes 
 Sequences in transcript 3’ UTRs can influence mRNA stability and gene 
expression by a number of mechanisms, including miRNA targeting, subcellular 
localization and regulation by RNA binding proteins.  Therefore, changes in 3’ 


























Figure 3.6. Validation of candidate APOBEC1 mRNA editing sites in small 
intestinal enterocytes.  Representative examples of conventional Sanger 
sequencing chromatograms for wild-type and apobec1-/- genomic DNA and 
cDNA at editing sites are shown. C-to-U(T) editing is apparent only in wild-
type cDNA.  (A) chr4:57203753(-) in the Ptpn3 transcript, (B) chr2:121978638(+) 
in the B2m transcript, (C) chr16:43981376(-) in the Gramd1c transcript, and (D) 
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Figure 3.7. Validation of APOBEC1 mRNA edit sites by subclone sequencing.  
gDNA and cDNA subclones from wild-type and apobec1-/-  enterocytes were 
sequenced by conventional Sanger techniques and aligned to transcript reference.  
Mismatches to reference are highlighted in yellow.  Arrows indicate candidate 
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Figure 3.7. Validation of APOBEC1 mRNA edit sites by subclone sequencing, 

























A 0 0 0 0
C 8 9 6 32
G 0 0 0 0
T 0 0 27 0























A 0 0 0 0
C 8 8 21 34
G 0 0 0 0
T 0 0 12 0























A 0 0 0 0
C 9 8 28 28
G 0 0 0 0
T 0 0 5 0























A 0 0 0 0
C 9 9 28 35
G 0 0 0 0
T 0 0 7 0
Subclones sequenced 9 9 35 35
gDNA cDNA
Figure 3.8. Validation of APOBEC1 mRNA edit sites by subclone sequencing. 
Nucleotide frequencies at candidate APOBEC1 editing sites of subclone 
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. . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
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. . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
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Reference Sequence A T A C A A T T T GA T C A GT A T A T T A A A GAT A A T T A T GA T C C A C A T GA C T T A A
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7











Figure 3.9. Hyperediting of apoB mRNA. Alignments of individual subclone 
sequences at apoB editing site (indicated by arrow). cDNA subclones from wild-
type and apobec1-/-  enterocytes were sequenced by conventional Sanger 
techniques and aligned to apoB reference.  Hyperediting is apparent in two wild-
type subclone sequences (arrowhead). 
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    wild-type  apobec1-/- 























chr12:8014860(+) Apob CDS C T 255 255 204 0.93  C 255 0 128 0.00 
chr2:121978638(+) B2m 3’UTR C Y 228 228 2860 0.18  C 255 0 1582 0.00 
chrX:109671648(+) 2010106E10Rik 3’UTR C Y 228 228 688 0.46  C 255 0 322 0.00 
chr8:46391931(-) Cyp4v3 3’UTR G R 228 228 112 0.38  G 117 0 42 0.00 
chr3:129616676(+) Casp6 3’UTR C Y 228 228 107 0.50  C 255 0 119 0.00 
chr17:44416335(+) Clic5 3’UTR C Y 175 175 186 0.31  C 255 0 92 0.01 
chr10:57235791(-) Serinc1 3’UTR G R 77 170 29 0.75  G 39 0 4 0.00 
chr5:87984364(-) Sult1d1 3’UTR G R 60 154 28 0.79  G 65 0 20 0.00 
chr2:143811725(-) Rrbp1 3’UTR G R 149 149 40 0.38  G 63 0 23 0.00 
chr10:7487994(-) BC013529 3’UTR G R 141 141 20 0.45  G 45 0 6 0.00 
chr9:79617629(-) Tmem30a 3’UTR G R 129 135 22 0.55  G 87 0 20 0.00 
chr1:152208563(-) BC003331 3’UTR G R 54 132 23 0.74  G 48 0 7 0.00 
chr4:57203753(-) Ptpn3 3’UTR G R 67 124 15 0.67  G 48 0 7 0.00 
chr16:77116537(+) Usp25 3’UTR C Y 116 116 16 0.50  C 45 0 6 0.00 
chr3:119135667(+) Dpyd 3’UTR C Y 115 115 26 0.32  C 63 0 12 0.00 
chr16:84955113(-) App 3’UTR G R 108 108 563 0.21  G 255 0 357 0.00 
chr13:96397289(-) Iqgap2 3’UTR G R 103 103 514 0.23  G 255 0 387 0.00 
chr3:144259976(+) Sep15 3’UTR C Y 93 103 13 0.54  C 42 0 5 0.00 
chrX:136207009(+) Rnf128 3’UTR C Y 91 91 669 0.20  C 255 0 397 0.00 
chrX:106355759(+) Sh3bgrl 3’UTR C Y 89 89 23 0.30  C 75 0 16 0.00 
chrX:50374459(+) Hprt1 3’UTR C Y 85 85 55 0.22  C 108 0 27 0.00 
chr4:94304303(-) Lrrc19 3’UTR G R 85 85 38 0.26  G 87 0 20 0.00 
chr3:119135669(+) Dpyd 3’UTR C Y 84 84 25 0.28  C 60 0 11 0.00 
chr14:73595382(-) Rb1 3’UTR G R 83 83 21 0.33  G 30 0 12 0.00 
chr12:85772761(-) Aldh6a1 3’UTR G R 64 80 9 0.56  G 42 0 5 0.00 
chr2:73654730(-) Atf2 3’UTR G R 73 73 21 0.29  G 54 0 9 0.00 
chr16:43981376(-) Gramd1c 3’UTR G R 64 64 17 0.29  G 51 0 8 0.00 
chr16:84954758(-) App 3’UTR G R 60 60 293 0.21  G 255 0 118 0.01 
chr10:69486962(+) Ank3 3’UTR C Y 56 56 11 0.36  C 36 0 3 0.00 
chr13:96397211(-) Iqgap2 3’UTR G R 55 55 124 0.38  G 150 0 41 0.00 
chr3:73442586(-) Bche 3’UTR G R 54 54 14 0.36  G 78 0 17 0.00 
chr1:192830761(-) Mfsd7b 3’UTR G A 2 48 9 0.78  G 42 0 5 0.00 
chr15:99239051(+) Tmbim6 3’UTR C Y 45 45 389 0.20  C 255 0 196 0.00 
Table 3.3.  Validated APOBEC1 editing sites (small intestinal enterocytes)
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Figure 3.10.  Editing frequency at APOBEC1 sites.  Sites were ranked by 
editing frequency, calculated as (# of T reads) / (# of C reads + # of T reads).  
In contrast to the efficiently edited apoB transcript, sites displayed a broad 
range of editing frequencies.  *apoB editing site.
100
 
example, more than 35% of the identified APOBEC1 editing sites are located 
within sequences that match the seed targets of known miRNAs (Table 3.4).  C-
to-U nucleotide changes at these sites could disrupt miRNA targeting and 
correspondingly affect transcript regulation. 
Though RNA-Seq was used primarily to screen for sequence mismatches 
indicative of APOBEC1 editing, the read datasets can also be used for 
quantifying transcript expression levels.  In order to compare transcript levels in 
wild-type and apobec1-/- enterocytes, whole-transcriptome expression profiling 
was carried out on the RNA-Seq reads generated for the mismatch screen.  
Comparative analysis indicated that many transcripts were differentially 
expressed, including a substantial number associated with lipid processing and 
transport.  However, of the transcripts containing 3’ UTR APOBEC1 editing sites, 
most were expressed at similar levels between samples (Figure 3.11).  Though a 
few were observed at different levels, greater than 2-fold alterations were not 
observed.  Therefore, though many transcripts are differentially expressed in 
wild-type and apobec1-/- enterocytes, possibly as a result of apoB-related lipid 
accumulation, no remarkable differences in expression at the transcript level 
were observed for APOBEC1 edit site-containing mRNAs.   
3.2.4.  APOBEC1 mRNA edit sites share characteristic sequence features 
Target recognition by RNA editing enzymes is typically determined by 
the sequence and/or structural context of the edited base (Bass, 2002; Davidson, 
2002).  Although features contributing to apoB mRNA editing have been 
previously characterized, it was unclear whether similar attributes would apply 









chr1:152208563 (-) NM_001077237 BC003331 mmu-miR-669b  
chr1:192830761 (-) NM_001081259 Mfsd7b   
chr2:73654730 (-) NM_009715 Atf2 mmu-miR-669n mmu-miR-297a 
mmu-miR-297b-5p 
mmu-miR-297c 
chr2:121978638 (+) NM_009735 B2m  mmu-miR-539 
chr2:143811725 (-) NM_133626 Rrbp1 mmu-miR-539  




chr3:119135667 (+) NM_170778 Dpyd   
chr3:119135669 (+) NM_170778 Dpyd   
chr3:129616676 (+) NM_009811 Casp6 mmu-miR-691  
chr3:144259976 (+) NM_053102 Sep15   
chr4:57203753 (-) NM_011207 Ptpn3  mmu-miR-154 
chr4:94304303 (-) NM_175305 Lrrc19   
chr5:87984364 (-) NM_016771 Sult1d1 mmu-miR-496  
chr8:46391931 (-) NM_133969 Cyp4v3   
chr9:79617629 (-) NM_133718 Tmem30a mmu-miR-190 
mmu-miR-190b 
chr10:7487994 (-) NM_145418 BC013529  mmu-miR-466l 
chr10:57235791 (-) NM_019760 Serinc1   
chr10:69486962 (+) NM_170729 Ank3   
chr12:85772761 (-) NM_134042 Aldh6a1   
chr13:96397211 (-) NM_027711 Iqgap2   
chr13:96397289 (-) NM_027711 Iqgap2 mmu-miR-370 
mmu-miR-683 
mmu-miR-323-3p 
chr14:73595382 (-) NM_009029 Rb1   
chr15:99239051 (+) NM_026669 Tmbim6   
chr16:43981376 (-) NM_153528 Gramd1c mmu-miR-1964  
chr16:77116537 (+) NM_013918 Usp25   
chr16:84954758 (-) NM_007471 App   
chr16:84955113 (-) NM_007471 App mmu-miR-186  
chr17:44416335 (+) NM_172621 Clic5 mmu-miR-143  
chrX:50374459 (+) NM_013556 Hprt1   
chrX:106355759 (+) NM_019989 Sh3bgrl   
chrX:109671648 (+) NM_026333 2010106E10Rik mmu-miR-142-3p  
chrX:136207009 (+) NM_023270 Rnf128   

























































































































Figure 3.11. Gene expression profiling for APOBEC1 mRNA editing targets.  
RNA-Seq transcriptome profiling analysis for wild-type and apobec1-/- small 
intestinal enterocytes was performed with the Cufflinks software package.  For 
each gene indicated, plotted values are the log2 fold-difference (wild-type : 
apobec1-/-) mRNA expression in RNA-Seq Reads Per Kilobase of exon model per 
Million mapped reads (RPKM).  Though subtle differences are apparent, 




share common cis features that might “mark” them for APOBEC1 editing, the 
sequences flanking the edited cytidines were further examined. 
APOBEC1 has RNA binding activity with a preference for sequences rich 
in A and U (Anant et al., 1995; Navaratnam et al., 1995).  The sequence region 
(101 nt) surrounding the apoB mRNA editing site is also particularly AU-rich 
(0.70 AU content).  The AU content of the APOBEC1 edit site 3’ UTRs was 
computed (0.63) and found to be significantly more AU-rich than comparable 
sets of 3’ UTRs chosen at random (Figure 3.12A, p < 0.0001).  Furthermore, 
within these AU-rich 3’ UTRs, the local regions (101 nt centered on site) 
containing the edit sites were further enriched for A and U bases (Figure 3.12B, p 
= 0.0006).  An example appears in Figure 3.13.  These results are consistent with a 
model in which APOBEC1 targets require a high AU sequence context for 
efficient editing. 
Aside from regional sequence content, other cytidine deaminases in the 
AID/APOBEC family exhibit strong preferences for particular bases immediately 
neighboring their editing targets (Beale et al., 2004).  Though potential 
preferences for APOBEC1 have been implied by in vitro RNA editing 
experiments (Backus and Smith, 1992; Chen et al., 1990; Shah et al., 1991), none 
have been rigorously investigated, likely due to the enzyme’s perceived 
specificity for a single mRNA substrate.  In alignments of the 3’ UTR edit sites 
identified here, almost all of the edited cytidines were immediately flanked by A 
or U bases at the -1 and +1 position (Figure 3.14, p = 7 x 10-5).  There were no 
significant nucleotide preferences at the  -4,-3,-2 and +2,+3,+4 positions relative 













































































































Figure 3.12.  Sequence features of APOBEC1 edit sites: AU content.  (A) AU 
content of random sets of 3’ UTRs.  The AU content of the set of the 29 edit site-
containing 3’ UTRs is 0.63.  AU content was computed for each of 100,000 
random sets of 29 3’ UTRs, and values were always less than 0.63.  Therefore, p < 
0.00001.  (B) AU content of random 101 nt windows within APOBEC1 editing 
site-containing 3’UTRs. The AU content of the 30 edit site-containing windows is 
0.69. The AU content for each of 100,000 random sets of 30 windows was 
computed and values were greater than or equal to 0.69 in only 0.02% of cases. 

























Figure 3.13. AU content in a sliding 101 nt window in the Tmbim6 3’ UTR.  The 




















































+1 +2 +3 +4 3'
A 11 15 7 22 0 18 9 11 15
C 3 4 7 0 32 0 5 8 4
G 6 5 6 1 0 1 6 4 4


























Figure 3.14.  Sequence features of APOBEC1 edit sites: Flanking nucleotides.  
(A) Frequency plot of bases flanking the APOBEC1 editing sites, aligned on the 
target cytidine.  (B) Base counts of nucleotides flanking the APOBEC1 editing 
sites.  The nucleotides immediately adjacent to the target cytidine tend 
overwhelmingly to be A or U.  P-values were computed using the binomial test. 






 DNA and RNA binding proteins often recognize and bind to specific 
sequence motifs in their molecular targets.  To ascertain whether the APOBEC1 
editing targets identified here share a common sequence element potentially 
important for editosome recognition, the Multiple Em for Motif Elicitation 
(MEME) algorithm (Bailey and Elkan, 1994) was used to analyze the sequence 
regions (101 nt centered on target C) surrounding the editing sites (Figure 3.15).  
MEME analysis revealed a significant 10 nt motif (log likelihood ratio = 157, E-
value = 8.8 x10-1, compared to 65 and 3 x 102 for shuffled sequence control) in 
regions adjacent to most (21/31) editing sites.  Next, the motif consensus 
sequence, WRAUYANUAU, was used to manually align the edit site-containing 
sequences (Figure 3.16).  Close or exact consensus motif matches were present 
downstream (3’) of almost every editing site, with most (24/32) appearing 4-6 nt 
from the target cytidine.  Of note, the consensus motif also matches the first 10 nt 
of the apoB mooring sequence, which is 5 nt downstream of its editing site 
(Backus and Smith, 1992; Shah et al., 1991).   
Taken together, these results indicate that 3’ UTR targets of APOBEC1 
editing are generally in AU-rich regions, immediately flanked by A or U 
nucleotides, and appear approximately 4-6 nt upstream of a mooring motif.  As 
these features are similar to those in the apoB mRNA (Smith et al., 2005), the 3’ 
UTR sites may be edited by a similar mechanism.     
3.2.5.  Sequence features are predictive for APOBEC1 editing in 3’ UTRs 
The set of newly identified target sites and their characteristic sequence 
features described above provide a refined list of criteria for sequences edited by 















3A 4U 5CU 6CGA 7GCA 8U 9GA 10CAU3!
Log likelihood ratio = 157
E-value = 8.8 x 10-1
Figure 3.15. Sequence motif identified by MEME analysis of regions flanking 
APOBEC1 editing sites.  This motif was derived from 21 of the 31 sequences 
analyzed.  Log likelihood ratio (157) and E-value (8.8 x10-1) are significant as 
compared to the “best” motif of a shuffled sequence control (Log likelihood ratio 
65, E-value 3 x 102).
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Editing Frequency
chr12:8014860(+) Apob 5'-- C A U A C G C G A U A C A A U U U G A U C A G U A U A U --3'
chr5:87984364(-) Sult1d1 5'-- U U A U U C A A A A U A C U C C A A A U U A U U A U U C --3'
chr1:192830761(-) Mfsd7b 5'-- U A U A U U C U G U U U C A U C A G A U U A C U A U A A --3'
chr10:57235791(-) Serinc1 5'-- U A G U A A A U C G A C U A G A A A A U U A G U A U G C --3'
chr1:152208563(-) BC003331 5'-- U A A U G A G C A G A C A A A A C G A U C A A U A U U G --3'
chr4:57203753(-) Ptpn3 5'-- C U A C U G A A A A A C A A C C U G A U C A A U A U A A --3'
chr12:85772761(-) Aldh6a1 5'-- U A A U G C A G A U A C A A A U A G A U C C U U A G A U --3'
chr9:79617629(-) Tmem30a 5'-- G G U A A C A U A U C A G U U U A G A U U A A U A U G U --3'
chr3:144259976(+) Sep15 5'-- A C A A U A A C U U A G U U U U G C A U G C U U A C A U --3'
chr16:77116537(+) Usp25 5'-- U A U A A A U A A U A C A A G G U G A U U A U U - U C A --3'
chr3:129616676(+) Casp6 5'-- A A A A A U A A U C C U C A G G A A A U U A C U A U G C --3'
chrX:109671648(+) 2010106E10Rik 5'-- G G A A A C A C U A C A A A U A U G A U U U C C A U G C --3'
chr10:7487994(-) BC013529 5'-- A G A A A C U G U A U C U A U U U G A U U A C U A U U G --3'
chr13:96397211(-) Iqgap2 5'-- U U U U U G U A A U G C U A U C A A A U C A G U A U C C --3'
chr8:46391931(-) Cyp4v3 5'-- G U U C U C A U U G A C U U G G A A A U U C A U A U A U --3'
chr2:143811725(-) Rrbp1 5'-- A G A U A A U U U C U C A U U A A A A U U C U U A U U U --3'
chr10:69486962(+) Ank3 5'-- U C A A G A A G A C A C A C U A A A A U U A C U A A A U --3'
chr3:73442586(-) Bche 5'-- A G U G A C A C A C U U A G C U C A A U G A C U A A U A --3'
chr14:73595382(-) Rb1 5'-- U U G A A A C U A U A C A U U C A A A U U G C U A U G U --3'
chr3:119135667/9(+) Dpyd 5'-- G U A A A U A G C A U C A C A U A A A U U C A U U U A U --3'
chr17:44416335(+) Clic5 5'-- G C A A G C U A C A U U C A U C U C A U U A U U A U G A --3'
chrX:106355759(+) Sh3bgrl 5'-- G U A A G G A U U U U A C A A A A A A U C A A U A U G C --3'
chr16:43981376(-) Gramd1c 5'-- A G U U U U A G A A G U C G U A A G A U U A U U A U A A --3'
chr2:73654730(-) Atf2 5'-- U U G U A U A A A C A C A C A A A A A U U A C - A U U U --3'
chr4:94304303(-) Lrrc19 5'-- C C A U A U A C A A C U G C C A U G A U U G A U A U U A --3'
chr13:96397289(-) Iqgap2 5'-- A C A C G G U G G A C A G C A G G U A U - A G - A C C C --3'
chrX:50374459(+) Hprt1 5'-- U G C G U C C C C A G A C U U U U G A U U U G C A C U A --3'
chr16:84954758(-) App 5'-- G C A G G A U G A U U G U A C A G A A U C A U U G C U U --3'
chr16:84955113(-) App 5'-- C U A C G U A U U C U U U U C C U G A U C A C U A U G C --3'
chr15:99239051(+) Tmbim6 5'-- U A C U U A G U G G U U U U C U C U A U U U U G A A A U --3'
chrX:136207009(+) Rnf128 5'-- U A U G A A C U G A A U U G G U U G A U C A G U A U A U --3'
chr2:121978638(+) B2m 5'-- A A A C C C U C U G U A C U U C U C A U U A C U - U G G --3'
W R A U Y A N U A UGenome Site Gene Consensus mooring motif:
Figure 3.16. Alignment of APOBEC1 target sequences by consensus sequence 
motif.  Edited cytidines are shaded blue.  Yellow shading indicates a match to the 
consensus sequence motif, represented in green.  Nearly every editing site is 
adjacent to at least a partially matched motif, most (24/32) within 4-6 nt.
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was composed, consisting of a cytidine flanked on both sides by either A or U 
and followed by an appropriately spaced mooring motif (WCWN2-
4WRAUYANUAU, Figure 3.17A).  In order to evaluate the distribution of 
potential APOBEC1 editing targets throughout the transcriptome, all mouse 
RefSeq exons were searched for this sequence pattern.  As enumerated in Figure 
3.17B, nearly 400 examples of this pattern were found in mouse mRNAs, 181 of 
which occurred in transcripts expressed in small intestine enterocytes (RNA-Seq 
analysis, RPKM ≥ 1.0).  Bypassing the comparative editing screen workflow, the 
sites were directly examined in the wild-type RNA-Seq read sequences at these 
sites for evidence of RNA editing.  Of the 74 patterns located in 3’ UTRs with 
read coverage (≥3 wild-type reads), detected C/T mismatches indicative of 
editing were detected at 32 sites.  Of the 34 patterns present in coding exons 
covered by RNA-Seq reads, only the apoB site displayed evidence of editing 
(Figure 3.17C).  A subset of these sites (7 in coding sequences, 14 in 3’ UTR 
sequences) was additionally examined by standard Sanger sequencing (Figure 
3.18).  Results confirmed C-to-U editing in 9 of the 3’ UTR sites but none of the 
coding sequence sites.  Though many of the sites described here were not 
detected in the RNA-Seq screen due to insufficient read coverage in the apobec1-/- 
library and/or relatively low editing frequencies, the APOBEC1 sequence 
pattern derived from the initially identified targets was predictive for additional 
APOBEC1 3’ UTR editing sites.    
These results suggest that while the APOBEC1 sequence pattern supports 
editing at numerous sites in transcript 3’ UTRs, it is not targeted when present in 


























Exon type:  5' UTR  CDS  3' UTR 
RefSeq transcripts 8 118 263
Expressed in enterocytes (RPKM 1.0) 1 45 135
wild-type RNA-Seq read coverage  3 0 34 74
Sites with C-T mismatch reads (> 0.075) NA 1 32
Figure 3.17. Sequence pattern prediction of APOBEC1 mRNA editing sites. 
(A) APOBEC1 editing site pattern used to search for additional targets in RefSeq 
transcripts. (B) Occurrences of APOBEC1 editing site pattern in RefSeq 
transcripts by type, listed by intestinal epithelium expression level and wild-type 
RNA-Seq read coverage.  (C)  Editing frequency at predicted APOBEC1 target 
sites as evaluated by wild-type read content.  With the exception of the apoB 
mRNA, no evidence of editing associated with the APOBEC1 sequence pattern 




Figure 3.18. Validation of candidate APOBEC1 mRNA editing sites predicted by 
sequence pattern search.  (A) Validation sequencing statistics.  Editing was detected 
in predicted 3’ UTRs, but not in coding sequences.  (B-C) Representative examples of 
conventional Sanger sequencing chromatograms for wild-type and apobec1-/- genomic 
DNA and cDNA at predicted editing sites are shown.(A) chrX:101478733(-) in the 
Abcb7 transcript, and (B) chr9:114658289(+) in the Cmtm6 transcript.






















A Exon type:  5' UTR  CDS  3' UTR 
Examined by Sanger sequencing NA 7 14
Confirmed APOBEC1 Editing NA 0 9
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mechanism of APOBEC1 sequence recognition and localization as well as the 
role for editing in 3’ UTRs. 
3.2.6.  APOBEC1 edit sites within evolutionarily conserved regions 
Compared to other non-coding sequences, functional elements within 3’ 
UTRs are more likely to be conserved throughout evolution. (Duret et al., 1993; 
Lipman, 1997). Upon inspection of the APOBEC1 editing sites, it appeared that 
many occur within regions of considerable phylogenetic conservation. Two 
examples are presented in Figure 3.19A and Figure 3.19B.  In order to 
systematically assess the conservation of sequence regions containing APOBEC1 
editing sites, a comparative evolutionary analysis was performed.  Conservation 
scores (phastCons scores for placental mammals (Siepel et al., 2005)) of 101 nt 
windows centered on the initially identified editing sites were compared to 
random 101 nt windows within the same 3’ UTRs (Figure 3.19C).  As a set, the 
regions containing APOBEC1 editing sites were significantly more conserved (P 
= 0.01), suggesting that these sequences may be of functional importance. 
Furthermore, in multispecies sequence alignments, it appeared that the 
APOBEC1 editing sites identified in mouse are often fixed as a C base (G base for 
(-)-strand transcripts) in mammalian evolution (Figure 3.20).  In addition, it 
seemed that when deviating from a C, other genomes most often contain a T (A 
for (-)-strand transcripts) at the aligned site.  This is not unexpected, as transition 
mutations are significantly more likely than transversion mutations, likely as a 
consequence of DNA synthesis and proofreading mechanisms (Collins and 
Jukes, 1994).  However, given the C-to-U converting function of APOBEC1, I 
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Figure 3.19. Phylogenetic conservation of regions containing APOBEC1 mRNA 
editing sites. (A and B)  Examples of APOBEC1 editing sites within well-
conserved regions.  Blue bars represent transcript 3’ UTRs.  Conservation plots 
depict phastCons scores for placental mammal multi-alignments.  Editing sites 
are indicated by green arrows.  (A) chr15:99239051(+) in the Tmbim6 transcript, 
(B) chr10:69486962(+) in the Ank3 transcript.  (C) Phylogenetic conservation for 
random sets of 101 nt windows within edit site-containing 3’ UTRs, as 
represented by mean phastCons scores for placental mammal multi-alignments. 
The mean phastCons score of the 30 edit site containing windows is 0.42.  The 
mean phastCons scores for each of 10,000 random sets of 30 windows was 
computed and values were greater than or equal to 0.42 in only 1% of the cases.  


































































chr1:152208563(-) C C - - T T T - T T G - C T - T T - T -
chr1:192830761(-) C - A - A A A A A - A - - A A G A A A A
chr2:73654730(-) C C C G C C C C C C - C C C - C C - C C
chr2:121978638(+) C C - - T T T T - T T - - - - - T - - -
chr2:143811725(-) C C T T T T T T T T C - - - - - - - - -
chr3:73442586(-) C C - - T - - T - - - - - - - T - - T -
chr3:119135667(+) C C T T C C C C C C C C C C - C - - C C
chr3:119135669(+) C T T T T A T T T T T T C T - T - - T T
chr3:129616676(+) C C - T C C C C C T - - - C - C C C C C
chr3:144259976(+) C C T - T T T T T T T G T T T T T T T T
chr4:57203753(-) C C C A C C C C C - C - - - - C C - C C
chr4:94304303(-) C T - T T T T T T - T - - C - T - T - T
chr5:87984364(-) C T - T T T T T T - T - - - - C - T - -
chr8:46391931(-) C C - C C C - C C C - C C C C C C - C C
chr9:79617629(-) C C A C - - - - - C C T C C - C C C C C
chr10:7487994(-) C C - C C C C C C - - C C C C C A C C C
chr10:57235791(-) C T T T T T T T T T T - - A - C - - T -
chr10:69486962(+) C C C C C C C C C C C C - C - C C C C C
chr12:85772761(-) C C T C C C C C C - C C C C C C C - C A
chr13:96397211(-) C - - - C C C C C C C C C C - C C C C C
chr13:96397289(-) C - - - T T T T T C T - T T - C C C C C
chr14:73595382(-) C C C C C C C C C C C C C C - C C T C C
chr15:99239051(+) C C C C C C C C C C C C C C C C C C C C
chr16:43981376(-) C C C C C C C C C - C - C C G C - C - T
chr16:77116537(+) C C C - C C C C C C T C - C - C C C C C
chr16:84954758(-) C C C C C C C C C C C C C C C C C C C C
chr16:84955113(-) C C C C C C C C C C C C C C - C C - C C
chr17:44416335(+) C C A C C C C C C C C - C C C T C C C -
chrX:50374459(+) C C C C C C C C C C - C A G - C C T C C
chrX:106355759(+) C C - T C - C C C C C - - A A A A - A -
chrX:109671648(+) C C - C C C C C C - - - - T - C - - C -

































































chr1:152 08563(-) C C - - T T T - T T G - C T - T T - T -
chr1:192830761(-) C - A - A A A A A - A - - A A G A A A A
chr2:73654730(-) C C C G C C C C C C - C C C - C C - C C
chr2:121978638(+) C C - - T T T T - T T - - - - - T - - -
chr2:14381 725(-) C C T T T T T T T T C - - - - - - - - -
chr3:734 2586(-) C C - - T - - T - - - - - - - T - - T -
chr3:1 91356 7(+) C C T T C C C C C C C C C C - C - - C C
chr3:1 91356 9(+) C T T T T A T T T T T T C T - T - - T T
chr3:129616 76(+) C C - T C C C C C T - - - C - C C C C C
chr3:14 259 76(+) C C T - T T T T T T T G T T T T T T T T
chr4:57203753(-) C C C A C C C C C - C - - - - C C - C C
chr4:94304303(-) C T - T T T T T T - T - - C - T - T - T
chr5:87984364(-) C T - T T T T T T - T - - - - C - T - -
chr8:46391931(-) C C - C C C - C C C - C C C C C C - C C
chr9:79617629(-) C C A C - - - - - C C T C C - C C C C C
chr10:74879 4(-) C C - C C C C C C - - C C C C C A C C C
chr10:57235791(-) C T T T T T T T T T T - - A - C - - T -
chr10:69486962(+) C C C C C C C C C C C C - C - C C C C C
chr12:857 2761(-) C C T C C C C C C - C C C C C C C - C A
chr13:9639721 (-) C - - - C C C C C C C C C C - C C C C C
chr13:96397289(-) C - - - T T T T T C T - T T - C C C C C
chr14:73595382(-) C C C C C C C C C C C C C C - C C T C C
chr15:9 239051(+) C C C C C C C C C C C C C C C C C C C C
chr16:43981376(-) C C C C C C C C C - C - C C G C - C - T
chr16:7 1 6537(+) C C C - C C C C C C T C - C - C C C C C
chr16:84954758(-) C C C C C C C C C C C C C C C C C C C C
chr16:8495 1 3(-) C C C C C C C C C C C C C C - C C - C C
chr17:4 163 5(+) C C A C C C C C C C C - C C C T C C C -
chrX:50374 59(+) C C C C C C C C C C - C A G - C C T C C
chrX:10635 759(+) C C - T C - C C C C C - - A A A A - A -
chrX:109671648(+) C C - C C C C C C - - - - T - C - - C -
chrX:1362070 9(+) C C C C C C C C C C C C C C - C C C C T
Figure 3.20.  Mouse APOBEC1 edit sites in placental mammal genome multi-
alignments. Multi-alignments of mouse APOBEC1 editing sites with 19 other 
placental mammal genomes are shown.  When an orthologous nucleotide in 
another mammal differs from the C in mouse, it is most often a T. This pattern is 
statistically significant (p = 0.03).   
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reflect functional sequence flexibility recapitulated in some species at the RNA 
level by APOBEC1.  The apparent C-T bias observed in multispecies alignments 
was quantitatively assessed by comparing the frequency of C-T bases occurring 
at positions aligned to mouse APOBEC1 editing sites to alignments at 
comparable random sites.  Mammalian genomic alignments to mouse APOBEC1 
editing sites are significantly more likely to contain C or T residues (P = 0.03), 
perhaps indicating a functional importance for either base. 
 
In summary, these results indicate that APOBEC1 site-specifically edits 
many mRNA transcripts other than apoB in small intestinal enterocytes and 




CHAPTER 4: DISCUSSION 
 The specific C-to-U base modification of apoB mRNA by APOBEC1 was 
the first example of mRNA editing observed in mammals (Chen et al., 1987) 
(Powell et al., 1987).  Since this discovery, extensive investigation has provided 
many details about the cofactors, evolution, regulation, and mechanism of 
APOBEC1 mRNA editing.  However, aside from the NF1 transcript in a subset of 
tumors (Mukhopadhyay et al., 2002; Skuse et al., 1996), no other physiological 
targets for APOBEC1 editing have been described.  The identification of 
additional mRNA editing sites has been limited, in part, by the technical 
challenge of detecting single nucleotide changes within entire transcriptomes.   
Recent technological advances now allow for DNA sequencing at a 
previously unprecedented scale.  This thesis presents the development of a novel 
methodology for the identification of mRNA editing sites by whole 
transcriptome sequencing.  The application of this RNA-Seq screening approach 
to small intestine enterocytes revealed previously undescribed APOBEC1 editing 
in numerous mRNA transcripts.  With the exception of the apoB mRNA, all 
newly identified APOBEC1 editing sites are within transcript 3’ UTRs.  All of 
these sites share several characteristic sequence features, including an AU-rich 
sequence context, a preference for A or U nucleotides immediately adjacent to 
the edited cytidine, and a downstream APOBEC1 mooring motif similar to that 
described for the apoB transcript.  These features proved to be predictive for 
APOBEC1 editing, and led to the identification of additional APOBEC1 3’ UTR 
sites that were not detected by the initial RNA-Seq screen.  Taken together, the 
results presented here dramatically expand the list of validated APOBEC1 
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mRNA editing targets in small intestinal enterocytes.  The recognition of these 
editing events and their localization to 3’ UTRs raises many questions about 
functional consequences and potential physiological roles for APOBEC1 beyond 
lipoprotein regulation.  
4.1.  APOBEC1 mRNA editing in transcript 3’ UTRs 
 In the case of apoB, the functional outcome of APOBEC1 editing can be 
inferred by basic sequence analysis: conversion of a glutamine codon (CAA) to a 
STOP codon (UAA) within a protein coding sequence results in translation of a 
truncated apoB-48 product.  However, predicting the function of 3’ UTR 
sequences pre- and/or post- editing is not as straightforward. 
 Though transcript 3’ UTRs do not encode protein sequence, they have 
been shown to regulate many aspects of mRNA stability and translational 
efficiency.  3’ UTRs are the primary site of gene regulation by miRNAs (Chi et al., 
2009; Grimson et al., 2007), which can mediate transcript degradation and/or 
translational suppression.  3’ UTRs can also contain sequence motifs and/or 
secondary structures important for the recruitment of various regulatory RNA 
binding proteins.  For example, AUUUA pentamers known as AU Rich Elements 
(AREs) are associated with transcript instability mediated by ARE-binding 
proteins (Barreau et al., 2005).  The 3’ UTRs of transcripts encoding cytokines and 
other immune mediators often contain variable numbers of AREs, which have 
been shown to participate in the temporal regulation of inflammatory gene 
expression (Hao and Baltimore, 2009).  Other transcripts can be regulated by 
structural elements of their 3’ UTRs.  For example, the VEGFA transcript 3’ UTR 
contains an RNA secondary structure that undergoes a conformational change in 
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response to environmental signals and consequently regulates VEGFA protein 
expression (Ray et al., 2009).  Additional regulatory functions attributed to 3’ 
UTR sequences include mRNA subcellular localization (Jambhekar and Derisi, 
2007; Jansen, 2001), translational selenocysteine incorporation (Berry et al., 1991), 
and transcript retention in the nucleus (Larocque et al., 2002). 
The distribution of APOBEC1 sites in coding sequence (apoB) as well as 
transcript 3’ UTRs is reminiscent of mRNA editing by ADARs.  Much like C-to-U 
deamination in apoB, some initial examples of A-to-I modification in mRNA 
were observed in tissue-specific transcripts (GluR, in the brain), which have 
protein coding sequences modified as a consequence of editing (Lomeli et al., 
1994).  Similar coding changes have been observed in several other neuronal 
transcripts (reviewed in Bass, 2002).  However, recent bioinformatic (Levanon et 
al., 2004) and ultra high-throughput sequencing analyses (Li et al., 2009b) have 
demonstrated that most A-to-I RNA editing occurs in non-coding RNA 
sequences, especially transcript 3’ UTRs.  As is the case for APOBEC1, ADAR 
editing varies in efficiency for different target transcripts (Li et al., 2009b). 
Though the functional consequences for most of these editing events remain 
largely unknown, several targets have been examined in some detail.  Evidence 
suggests that A-to-I editing in 3’ UTR sequence can induce nuclear retention of 
transcripts (Chen et al., 2008), target mRNA cleavage (Osenberg et al., 2009), and 
potentially modify miRNA target sites to modulate gene expression (Borchert et 
al., 2009; Liang and Landweber, 2007). 
The recent evidence that ADAR editing of transcript 3’ UTRs can affect 
post-transcriptional regulation of RNA provides illustrative examples of how 
changes in non-coding sequence can impact genetic output.  Might APOBEC1 
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editing of 3’ UTRs have similar functional consequences?  Based on the sequence 
context of the identified edit sites, a number of regulatory possibilities can be 
envisioned.  First, APOBEC1 editing events in four transcript 3’ UTRs are 
predicted to generate new AREs.  For example, in the Tmbim6 transcript 3’ UTR, 
APOBEC1 editing converts ACUUA to AUUUA, a canonical ARE.  As the 
number of AREs contained within a transcript 3’ UTR has been shown to 
inversely correlate with mRNA stability (Hao and Baltimore, 2009), generating 
additional AREs could destabilize an edited transcript.  Furthermore, because the 
edited 3’ UTRs are high in overall AU content, several already contain AREs 
other than those generated by APOBEC1 editing.  It is possible that introduction 
of an additional ARE could contribute to the fine-tuning of transcript stability.  
Of note, though editing was not observed, APOBEC1 has been reported to bind 
and stabilize AU-rich 3’ UTRs (Anant and Davidson, 2000; Anant et al., 2004).  
Perhaps APOBEC1 can modulate mRNA stability through editing-dependent 
and –independent mechanisms. 
Alteration of miRNA targets represents another possible functional 
consequence of 3’ UTR editing.  3’ UTRs represent the principle targets of 
transcript regulation by miRNAs.  More than 35% of APOBEC1 editing sites are 
located within sequences that match the seed targets of known miRNAs.  
Cytidine deamination at these sites modifies target sequences and could 
potentially abolish miRNA binding.  Conversely, APOBEC1 editing could 
introduce new miRNA seed target sequences, or shift existing targets to 
sequences that recruit different miRNAs.  It should be noted that miRNA 
targeting is enhanced within regions rich in A and U nucleotides (Grimson et al., 
2007), a prominent feature of APOBEC1 editing sites.  Though most edited 
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transcripts were measured at similar levels by RNA-Seq profiling, several were 
1.5 – 2.0 fold differentially expressed (wild-type vs. apobec1-/-), differences 
consistent with miRNA regulation.  Furthermore, as miRNA targeting in 
vertebrates may primarily affect translation rather than mRNA degradation 
(Jackson and Standart, 2007; Standart and Jackson, 2007), alterations due to 
editing might not be apparent at the transcript level. 
Without flexible mouse enterocyte models that can manipulated in vitro, 
direct experimental evidence for the functional and physiological relevance of 
these editing events would require detection of altered translational outcomes in 
APOBEC1-expressing enterocytes in vivo. Furthermore, apobec1-/- epithelial cells 
accumulate triacylglycerol lipids due to apoB-related deficiencies in chylomicron 
formation (Kendrick et al., 2001).  Therefore, direct regulatory effects due to the 
absence of 3’ UTR editing of various target transcripts are difficult to evaluate, as 
they may be obscured by the indirect cellular effects of the absence of apoB 
editing on lipid metabolism. For these technical reasons, experimental evidence 
for the importance of APOBEC1 editing has been elusive.  However, the 
localization of many APOBEC1 edit sites within regions conserved throughout 
mammalian evolution implies potential functional relevance.  Indeed, the 
APOBEC1 editing sites are significantly more likely to occur within highly 
conserved sequence regions than in other, less conserved 3’ UTR sequences.  
Furthermore, though analysis was limited by a relatively small sample set (n = 32 
sites), editing sites in mouse transcripts tend to be maintained as genomic Cs or 
Ts throughout mammalian evolution significantly more so than would be 
expected at background phylogenetic transition rates (p=0.03).  This observation 
could be indicative of a mechanism whereby APOBEC1 “corrects” a genomic 
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cytidine mutation to an appropriate T within specific tissues and/or under 
certain conditions.  Alternatively, APOBEC1 editing may provide a means of 
“genetic dosing” at specific nucleotide positions, thereby adding adaptive 
flexibility at the transcript level to sequences hard coded in the genome, as has 
been recently proposed for ADARs (Gommans et al., 2009). 
4.2.  Sequence features of APOBEC1 mRNA editing targets in 3’ UTRs 
Without evidence of additional mRNA targets, most characterizations of 
the sequence and structural requirements for APOBEC1 editing have been based 
on the apoB transcript.  Early studies demonstrated that editing required a 
downstream mooring sequence separated from the target cytidine by a short 
spacer element (Backus and Smith, 1992; Shah et al., 1991).  The size of the spacer 
element was found to be somewhat flexible; acceptable lengths ranged from 4 to 
7 nt, with an optimal distance of 5 nt.  Similarly, editing activity can tolerate 
mooring sequence point mutations at some positions but not others (Shah et al., 
1991).  However, these analyses were limited only to transversion mutations, and 
may have overlooked additional sequence flexibility. 
 Analysis of the numerous mRNA targets identified here demonstrate 
flexibility in the sequence requirements for APOBEC1 editing consistent with, 
but not apparent in, previous studies of apoB.  The consensus mooring motif 
derived from the newly identified targets implies some rigid sequence 
constraints, notably at position 3 (A) and position 4 (U).  These apparent 
constrains are consistent with the in vitro analysis of the apoB mRNA; point 
mutation at these positions completely abrogated editing by APOBEC1 (Shah et 
al., 1991).  However, it appears that other positions tolerate different nucleotides 
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than those described for apoB.  For example, most targets contain a G or an A at 
position 2, suggesting a purine requirement.  Similarly, most targets contain a C 
or a U at position 5, indicating a likely pyrimidine constraint.  The flexibility 
limited to nucleotides with similar aromatic rings may reflect certain structural 
requirements of the APOBEC1 active site and/or the RNA binding components 
of the editosome.  In current mechanistic models for apoB mRNA editing, ACF 
binds the mooring sequence, and its appropriate spacing ensures proper 
placement of the target cytidine in the APOBEC1 active site (Maris and Allain, 
2009).  The recognition of similar mooring sequences in 3’ UTR targets suggests 
that editing of these sites proceeds by a similar mechanism.  The strong 
preference observed for A and U nucleotides immediately flanking the edit sites 
has not been previously described, though the edited cytidine in apoB mRNA is 
bordered by As.  Perhaps these flanking nucleotides fulfill an additional 
structural or mechanistic requirement for proper positioning and deamination in 
the APOBEC1 active site. 
 Feature characterization of multiple APOBEC1 mRNA edit sites has also 
provided a flexible sequence pattern for robust bioinformatic prediction of 
additional transcript targets.  Previous computational attempts to identify 
APOBEC1 edit sites in sequence databases were limited by patterns derived 
solely from the apoB mRNA and related experimentation.  For example, 
sequence queries using weighted matrix motif models developed from apoB 
mooring sequence point mutagenesis studies identified numerous candidate 
APOBEC1 editing sites throughout the transcriptome (Smith et al., 2005).  
However, editing was not detected at any of the sites examined.  Therefore, 
though required for editing, the mooring sequence alone is not adequately 
124
 
predictive for APOBEC1 mRNA substrates.  In contrast, the refined sequence 
pattern derived from the collection of targets reported here was sufficient to 
identify numerous additional APOBEC1 sites that were not detected by the 
RNA-Seq screen.  These results further support a model for APOBEC1 target 
recognition compatible with but more complex than that presumed from apoB 
mRNA editing. 
4.3.  APOBEC1 mRNA editing appears to be constrained to 3’ UTRs 
The localization of all newly identified editing sites to transcript 3’ UTRs 
raises questions about the mechanism of apoB mRNA coding sequence editing 
by APOBEC1.  Despite the presence of sequence motifs consistent with 
APOBEC1 editing within coding and untranslated sequences throughout the 
transcriptome, RNA-Seq data suggest that APOBEC1 only acts on those targets 
located in 3’ UTRs.  Thus, with regard to APOBEC1 targeting, apoB coding 
sequence editing appears to be the exception rather than the rule.  How is the 
APOBEC1 editosome targeted to its apparent recognition motif in apoB mRNA 
and transcript 3’ UTRs but not to similar motifs in other coding sequences?  Prior 
to the identification of the additional editing sites described here, it was 
proposed that the RNA splicing machinery physically obscures the sizeable 
editosome from access to most coding exons, restricting editing to a post-
splicing, pre-nuclear-export temporal window (Sowden et al., 1996b; Sowden 
and Smith, 2001).  In this model, the apoB target remains accessible because the 
APOBEC1 target site is located near the midpoint of a particularly large (>7 kb) 
exon and therefore sufficiently distant from exon-intron boundaries and the 
spliceosome protein complexes associated with them.  Such a mechanism might 
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allow for the editing of 3’ UTR sites observed here.   A similar possibility might 
involve a more specific exclusion of APOBEC1 from all coding sequences in 
order to protect them from off-target editing.  This exclusionary mechanism 
could be bypassed at the apoB edit site by an additional targeting factor within 
the editosome, on the apoB mRNA, or both. It is interesting to note that upon 
apoB mRNA editing by APOBEC1 the downstream coding sequence becomes a 
3’ UTR.  This may represent an important link regarding the relationship of this 
well-known mRNA editing target to the 3’ UTR editing sites described here. 
4.4.  Functions for APOBEC1 beyond the small intestine 
 In many mammals, APOBEC1 expression is not restricted to the small 
intestine.  For example, murine APOBEC1 is also expressed in liver, kidney, 
muscle and spleen (Nakamuta et al., 1995).  APOBEC1 expression has been 
detected in immune cell subsets, including macrophages, dendritic cells and B 
cells.  Furthermore, expression in these cell types is upregulated by TLR stimuli 
such as LPS and poly(I:C).  However, the function of APOBEC1 in these cells is 
unclear, as the apoB transcript is not expressed.  Given the expression pattern in 
immune cells and the host defense functions of many related AID/APOBEC 
cytidine deaminases, perhaps APOBEC1 editing functions in the immune 
system.  If true, one might expect a readily observable immune phenotype in 
apobec1-/- mice, which has not been described.  However, despite extensive 
experimentation, apobec1-/- animals have been used primarily for the study of 
apoB mRNA editing and its physiological effects on lipid regulation.  
Furthermore, an immune phenotype might only be apparent in a specific context, 
i.e. infection with a particular pathogen.  For example, though APOBEC3 is an 
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effective inhibitor of retroviral infection, apobec3-/- mice are healthy and 
phenotypically normal on gross examination (Mikl et al., 2005).  However, upon 
infection with Moloney murine leukemia virus (Low et al., 2009) or murine 
mammary tumor virus (Okeoma et al., 2009), apobec3-/- mice exhibit deficiencies 
in viral control as compared to wild-type animals.   
The recognition that APOBEC1 editing is not restricted solely to the apoB 
mRNA raises the possibility that APOBEC1 might edit other transcripts in 
immune cells.  Application of the comparative RNA-Seq screen to the immune 
cells of steady state and/or infected wild-type and apobec1-/- mice will likely 
provide insight as to potential mRNA editing targets and functions for 
APOBEC1 in host defense. 
4.5.  Comparative RNA-Seq screen for the study of mRNA editing: Advantages 
and disadvantages 
 The recent advances in sequencing technologies offer new and powerful 
tools with which to study cellular transcriptomes.  Several ultra-high throughput 
sequencing methods have been applied to RNA editing problems, and each has a 
distinct set of advantages and drawbacks.  Though very effective in identifying 
mRNA targets of APOBEC1 editing, the comparative RNA-Seq screening 
approach presented here is no exception.  Perhaps most importantly, the 
comparative screen is not biased by any presuppositions or assumptions 
regarding potential editing targets; sites are identified strictly through the 
detection of single nucleotide mismatches.  This contrasts with recent ADAR 
editing studies that used ultra-high throughput sequencing to confirm editing 
sites predicted by sequence context and/or EST database analysis (Li et al., 
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2009b). Furthermore, compared to sequence capture techniques, RNA-Seq is 
considerably more cost effective in sample preparation and analysis. Next, as a 
comparative technique with a controlled variable (plus/minus editing activity), 
editing events can be assigned to a specific enzyme, in this case APOBEC1.  
Finally, in addition to the nucleotide mismatches indicative of editing, RNA-Seq 
datasets can provide extensive supplemental information regarding transcript 
expression, splicing, relative isoform abundance, and promoter usage.  Though 
not required for edit site identification, such information can be useful in 
interpreting the functional consequences of mRNA modifications. 
 The primary disadvantage of an RNA-Seq approach to editing is that 
transcripts expressed at low levels are likely to be underrepresented in 
sequencing datasets.  Sequencing coverage is directly proportional to transcript 
expression level (Mortazavi et al., 2008), and transcripts with insufficient 
coverage cannot be interrogated for potential mismatches.  This problem is 
evident in the identification and validation of several sequence-predicted editing 
targets that were overlooked by the RNA-Seq screen due to inadequate read 
coverage.  This limitation can be overcome by sequencing RNA-Seq libraries at 
additional read depth.  Next, as a comparative screen, this technique requires  
“editing enzyme-competent” and “editing enzyme-deficient” samples.  As 
demonstrated for APOBEC1, congenic knockout mice are an ideal source of 
experimental material.  However, as is the case for ADAR1 (Hartner et al., 2004; 
Wang et al., 2004b), certain RNA editing enzymes may be essential for 
development and viability.  Furthermore, a requirement for genetically modified 
organisms eliminates the possibility of studies with human tissue.  These issues 
could be addressed by conditional deletion and/or RNAi knockdown strategies.  
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Finally, in its current form, the comparative screen uses only polyA+ mRNA in 
RNA-Seq library preparation.  As a result, it cannot detect editing events in 
transcripts that are not polyadenylated, including various non-coding RNAs and 
miRNAs.  This limitation can be circumvented through different RNA isolation 
protocols, such as negative selection methods that deplete ribosomal RNA from 
total RNA preparations.     
4.6.  Comparative RNA-Seq mRNA editing screen: Additional applications 
 The successful development and application of an RNA-Seq screening 
approach to identify mRNA editing sites provides an opportunity to address 
many additional questions about RNA editing enzymes and their targets.  This 
methodology can be easily adapted and applied to a variety of editing enzymes 
in diverse organisms and tissues.  As described above, a characterization of C-to-
U editing in immune cells would be helpful in understanding possible functions 
for APOBEC1 in host defense.  The screen could also be applied to cytidine 
deaminases without known targets; a whole-transcriptome comparison of wild-
type and apobec2-/- muscle (Mikl et al., 2005) might elucidate the long sought-after 
substrate(s) for APOBEC2.  An investigation of potential AID mRNA editing is 
another intriguing possibility.  Upon its initial discovery, AID was thought to be 
an RNA editor on account of its homology to APOBEC1 (Muramatsu et al., 1999).  
Though since demonstrated to act on genomic DNA, the possibility of additional 
RNA substrates for AID has not been ruled out (Shivarov et al., 2008).  However, 
though a complete analysis is pending, a preliminary RNA-Seq screening 




 Though effective for APOBEC1, the comparative RNA-Seq screen is not 
limited to editing targets of cytidine deaminases.  Identifying RNA editing 
events in the recently developed conditional ADAR1 deletion mouse system 
(XuFeng et al., 2009) could supplement and assign specificity to many recently 
described A-to-I editing targets.  In addition, there are many outstanding 
questions regarding RNA editing in other non-mammalian species that could be 
similarly addressed.  For example, C-to-U mRNA editing was recently observed 
in C. elegans; the extent of its activity and function remain largely unknown 
(Wang et al., 2004a).  Finally, this methodology is not strictly limited to the study 
of RNA editing.  A similar transcriptomics workflow can be utilized for any 
comparative evaluation of single nucleotide differences in mRNA.  For example, 
“expressed mutations” (i.e. genomic mutations in transcribed exons) could be 
evaluated in tumor versus healthy control tissue from the same patient.  Such an 
analysis might reveal point mutations, insertions and/or deletions associated 
with oncogenesis while simultaneously providing gene expression profiling 
data.  These and other applications illustrate the potential versatility of this 
transcriptomics methodology. 
4.7.  Closing remarks 
Recent technological advances allow for the study of genomes and 
transcriptomes on a formerly unprecedented scale.  As more data become 
available, it is increasingly apparent that the transcriptome is far more dynamic 
and complex than previously anticipated. RNA transcripts can undergo a wide 
variety of alterations, including splicing, cleavage, base modification and editing.  
Such mechanisms introduce considerable diversity to the transcriptome and, by 
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extension, to the expressed proteome.  RNA editing is one mechanism by which 
the expressed information content of a gene can be altered without modifying 
the genome itself. 
 As the information encoded in an mRNA transcript can affect a protein’s 
sequence and the regulation of its expression, mRNA editing can impact several 
different aspects of the cellular proteome.  In the case of ADARs, editing in 
coding sequences gives rise to functionally distinct proteins and editing in 3’ 
UTRs affects transcript regulation and expression.  Though long thought 
monospecific for the apoB coding sequence, the findings presented here 
demonstrate that APOBEC1 edits numerous mRNAs in small intestinal 
enterocytes.  The localization of these newly identified editing events to 3’ UTRs 
suggests that they may play a role in transcript regulation. These results also 
imply additional functions for this cytidine deaminase beyond its characterized 
role in lipid transport, both in small intestinal enterocytes as well as other cell 
types.  Furthermore, the number and diversity of APOBEC1 targets identified 
provides an example of the additional complexity introduced to a cellular 
transcriptome by RNA editing.  Such informational diversity, whether mediated 
by APOBEC1 or other RNA editing enzymes, demonstrates one aspect of the 
flexible and dynamic nature of mRNA transcripts, which were originally thought 
to be static facsimiles of genetic content.  The trancriptomics methodology 
presented here will be useful in understanding the informational diversity 
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